false --12-31 2025 Q3 0001471781 0001471781 2025-01-01 2025-09-30 0001471781 2025-11-14 0001471781 2025-09-30 0001471781 2024-12-31 0001471781 us-gaap:SeriesBPreferredStockMember 2025-09-30 0001471781 us-gaap:SeriesBPreferredStockMember 2024-12-31 0001471781 us-gaap:SeriesCPreferredStockMember 2025-09-30 0001471781 us-gaap:SeriesCPreferredStockMember 2024-12-31 0001471781 us-gaap:SeriesHPreferredStockMember 2025-09-30 0001471781 us-gaap:SeriesHPreferredStockMember 2024-12-31 0001471781 GTCH:SeriesIPreferredStockMember 2025-09-30 0001471781 GTCH:SeriesIPreferredStockMember 2024-12-31 0001471781 2025-07-01 2025-09-30 0001471781 2024-07-01 2024-09-30 0001471781 2024-01-01 2024-09-30 0001471781 us-gaap:SeriesBPreferredStockMember 2023-12-31 0001471781 us-gaap:SeriesCPreferredStockMember 2023-12-31 0001471781 us-gaap:SeriesHPreferredStockMember 2023-12-31 0001471781 GTCH:SeriesIPreferredStockMember 2023-12-31 0001471781 us-gaap:CommonStockMember 2023-12-31 0001471781 us-gaap:TreasuryStockCommonMember 2023-12-31 0001471781 GTCH:ShareToBeCancelledMember 2023-12-31 0001471781 GTCH:StockLoanReceivableMember 2023-12-31 0001471781 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001471781 us-gaap:RetainedEarningsMember 2023-12-31 0001471781 us-gaap:NoncontrollingInterestMember 2023-12-31 0001471781 2023-12-31 0001471781 us-gaap:SeriesBPreferredStockMember 2024-03-31 0001471781 us-gaap:SeriesCPreferredStockMember 2024-03-31 0001471781 us-gaap:SeriesHPreferredStockMember 2024-03-31 0001471781 GTCH:SeriesIPreferredStockMember 2024-03-31 0001471781 us-gaap:CommonStockMember 2024-03-31 0001471781 us-gaap:TreasuryStockCommonMember 2024-03-31 0001471781 GTCH:ShareToBeCancelledMember 2024-03-31 0001471781 GTCH:StockLoanReceivableMember 2024-03-31 0001471781 us-gaap:AdditionalPaidInCapitalMember 2024-03-31 0001471781 us-gaap:RetainedEarningsMember 2024-03-31 0001471781 us-gaap:NoncontrollingInterestMember 2024-03-31 0001471781 2024-03-31 0001471781 us-gaap:SeriesBPreferredStockMember 2024-06-30 0001471781 us-gaap:SeriesCPreferredStockMember 2024-06-30 0001471781 us-gaap:SeriesHPreferredStockMember 2024-06-30 0001471781 GTCH:SeriesIPreferredStockMember 2024-06-30 0001471781 us-gaap:CommonStockMember 2024-06-30 0001471781 us-gaap:TreasuryStockCommonMember 2024-06-30 0001471781 GTCH:ShareToBeCancelledMember 2024-06-30 0001471781 GTCH:StockLoanReceivableMember 2024-06-30 0001471781 us-gaap:AdditionalPaidInCapitalMember 2024-06-30 0001471781 us-gaap:RetainedEarningsMember 2024-06-30 0001471781 us-gaap:NoncontrollingInterestMember 2024-06-30 0001471781 2024-06-30 0001471781 us-gaap:CommonStockMember 2024-12-31 0001471781 us-gaap:TreasuryStockCommonMember 2024-12-31 0001471781 GTCH:ShareToBeCancelledMember 2024-12-31 0001471781 GTCH:StockLoanReceivableMember 2024-12-31 0001471781 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001471781 us-gaap:RetainedEarningsMember 2024-12-31 0001471781 us-gaap:NoncontrollingInterestMember 2024-12-31 0001471781 us-gaap:SeriesBPreferredStockMember 2025-03-31 0001471781 us-gaap:SeriesCPreferredStockMember 2025-03-31 0001471781 us-gaap:SeriesHPreferredStockMember 2025-03-31 0001471781 GTCH:SeriesIPreferredStockMember 2025-03-31 0001471781 us-gaap:CommonStockMember 2025-03-31 0001471781 us-gaap:TreasuryStockCommonMember 2025-03-31 0001471781 GTCH:ShareToBeCancelledMember 2025-03-31 0001471781 GTCH:StockLoanReceivableMember 2025-03-31 0001471781 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0001471781 us-gaap:RetainedEarningsMember 2025-03-31 0001471781 us-gaap:NoncontrollingInterestMember 2025-03-31 0001471781 2025-03-31 0001471781 us-gaap:SeriesBPreferredStockMember 2025-06-30 0001471781 us-gaap:SeriesCPreferredStockMember 2025-06-30 0001471781 us-gaap:SeriesHPreferredStockMember 2025-06-30 0001471781 GTCH:SeriesIPreferredStockMember 2025-06-30 0001471781 us-gaap:CommonStockMember 2025-06-30 0001471781 us-gaap:TreasuryStockCommonMember 2025-06-30 0001471781 GTCH:ShareToBeCancelledMember 2025-06-30 0001471781 GTCH:StockLoanReceivableMember 2025-06-30 0001471781 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0001471781 us-gaap:RetainedEarningsMember 2025-06-30 0001471781 us-gaap:NoncontrollingInterestMember 2025-06-30 0001471781 2025-06-30 0001471781 us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-03-31 0001471781 us-gaap:SeriesCPreferredStockMember 2024-01-01 2024-03-31 0001471781 us-gaap:SeriesHPreferredStockMember 2024-01-01 2024-03-31 0001471781 GTCH:SeriesIPreferredStockMember 2024-01-01 2024-03-31 0001471781 us-gaap:CommonStockMember 2024-01-01 2024-03-31 0001471781 us-gaap:TreasuryStockCommonMember 2024-01-01 2024-03-31 0001471781 GTCH:ShareToBeCancelledMember 2024-01-01 2024-03-31 0001471781 GTCH:StockLoanReceivableMember 2024-01-01 2024-03-31 0001471781 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-03-31 0001471781 us-gaap:RetainedEarningsMember 2024-01-01 2024-03-31 0001471781 us-gaap:NoncontrollingInterestMember 2024-01-01 2024-03-31 0001471781 2024-01-01 2024-03-31 0001471781 us-gaap:SeriesBPreferredStockMember 2024-04-01 2024-06-30 0001471781 us-gaap:SeriesCPreferredStockMember 2024-04-01 2024-06-30 0001471781 us-gaap:SeriesHPreferredStockMember 2024-04-01 2024-06-30 0001471781 GTCH:SeriesIPreferredStockMember 2024-04-01 2024-06-30 0001471781 us-gaap:CommonStockMember 2024-04-01 2024-06-30 0001471781 us-gaap:TreasuryStockCommonMember 2024-04-01 2024-06-30 0001471781 GTCH:ShareToBeCancelledMember 2024-04-01 2024-06-30 0001471781 GTCH:StockLoanReceivableMember 2024-04-01 2024-06-30 0001471781 us-gaap:AdditionalPaidInCapitalMember 2024-04-01 2024-06-30 0001471781 us-gaap:RetainedEarningsMember 2024-04-01 2024-06-30 0001471781 us-gaap:NoncontrollingInterestMember 2024-04-01 2024-06-30 0001471781 2024-04-01 2024-06-30 0001471781 us-gaap:SeriesBPreferredStockMember 2024-07-01 2024-09-30 0001471781 us-gaap:SeriesCPreferredStockMember 2024-07-01 2024-09-30 0001471781 us-gaap:SeriesHPreferredStockMember 2024-07-01 2024-09-30 0001471781 GTCH:SeriesIPreferredStockMember 2024-07-01 2024-09-30 0001471781 us-gaap:CommonStockMember 2024-07-01 2024-09-30 0001471781 us-gaap:TreasuryStockCommonMember 2024-07-01 2024-09-30 0001471781 GTCH:ShareToBeCancelledMember 2024-07-01 2024-09-30 0001471781 GTCH:StockLoanReceivableMember 2024-07-01 2024-09-30 0001471781 us-gaap:AdditionalPaidInCapitalMember 2024-07-01 2024-09-30 0001471781 us-gaap:RetainedEarningsMember 2024-07-01 2024-09-30 0001471781 us-gaap:NoncontrollingInterestMember 2024-07-01 2024-09-30 0001471781 us-gaap:SeriesBPreferredStockMember 2025-01-01 2025-03-31 0001471781 us-gaap:SeriesCPreferredStockMember 2025-01-01 2025-03-31 0001471781 us-gaap:SeriesHPreferredStockMember 2025-01-01 2025-03-31 0001471781 GTCH:SeriesIPreferredStockMember 2025-01-01 2025-03-31 0001471781 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0001471781 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0001471781 GTCH:ShareToBeCancelledMember 2025-01-01 2025-03-31 0001471781 GTCH:StockLoanReceivableMember 2025-01-01 2025-03-31 0001471781 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0001471781 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0001471781 us-gaap:NoncontrollingInterestMember 2025-01-01 2025-03-31 0001471781 2025-01-01 2025-03-31 0001471781 us-gaap:SeriesBPreferredStockMember 2025-04-01 2025-06-30 0001471781 us-gaap:SeriesCPreferredStockMember 2025-04-01 2025-06-30 0001471781 us-gaap:SeriesHPreferredStockMember 2025-04-01 2025-06-30 0001471781 GTCH:SeriesIPreferredStockMember 2025-04-01 2025-06-30 0001471781 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0001471781 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0001471781 GTCH:ShareToBeCancelledMember 2025-04-01 2025-06-30 0001471781 GTCH:StockLoanReceivableMember 2025-04-01 2025-06-30 0001471781 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0001471781 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0001471781 us-gaap:NoncontrollingInterestMember 2025-04-01 2025-06-30 0001471781 2025-04-01 2025-06-30 0001471781 us-gaap:SeriesBPreferredStockMember 2025-07-01 2025-09-30 0001471781 us-gaap:SeriesCPreferredStockMember 2025-07-01 2025-09-30 0001471781 us-gaap:SeriesHPreferredStockMember 2025-07-01 2025-09-30 0001471781 GTCH:SeriesIPreferredStockMember 2025-07-01 2025-09-30 0001471781 us-gaap:CommonStockMember 2025-07-01 2025-09-30 0001471781 us-gaap:TreasuryStockCommonMember 2025-07-01 2025-09-30 0001471781 GTCH:ShareToBeCancelledMember 2025-07-01 2025-09-30 0001471781 GTCH:StockLoanReceivableMember 2025-07-01 2025-09-30 0001471781 us-gaap:AdditionalPaidInCapitalMember 2025-07-01 2025-09-30 0001471781 us-gaap:RetainedEarningsMember 2025-07-01 2025-09-30 0001471781 us-gaap:NoncontrollingInterestMember 2025-07-01 2025-09-30 0001471781 us-gaap:SeriesBPreferredStockMember 2024-09-30 0001471781 us-gaap:SeriesCPreferredStockMember 2024-09-30 0001471781 us-gaap:SeriesHPreferredStockMember 2024-09-30 0001471781 GTCH:SeriesIPreferredStockMember 2024-09-30 0001471781 us-gaap:CommonStockMember 2024-09-30 0001471781 us-gaap:TreasuryStockCommonMember 2024-09-30 0001471781 GTCH:ShareToBeCancelledMember 2024-09-30 0001471781 GTCH:StockLoanReceivableMember 2024-09-30 0001471781 us-gaap:AdditionalPaidInCapitalMember 2024-09-30 0001471781 us-gaap:RetainedEarningsMember 2024-09-30 0001471781 us-gaap:NoncontrollingInterestMember 2024-09-30 0001471781 2024-09-30 0001471781 us-gaap:CommonStockMember 2025-09-30 0001471781 us-gaap:TreasuryStockCommonMember 2025-09-30 0001471781 GTCH:ShareToBeCancelledMember 2025-09-30 0001471781 GTCH:StockLoanReceivableMember 2025-09-30 0001471781 us-gaap:AdditionalPaidInCapitalMember 2025-09-30 0001471781 us-gaap:RetainedEarningsMember 2025-09-30 0001471781 us-gaap:NoncontrollingInterestMember 2025-09-30 0001471781 GTCH:VisionWaveHoldingMember 2024-03-19 2024-03-20 0001471781 GTCH:TokenizeMember 2024-03-19 2024-03-20 0001471781 GTCH:TokenizeMember 2025-01-01 2025-09-30 0001471781 GTCH:TokenizeholdingsinVisionWaveMember 2025-01-01 2025-09-30 0001471781 GTCH:GBTTokenizeCorpMember 2025-01-01 2025-09-30 0001471781 GTCH:GBTTechnologiesIncMember 2025-01-01 2025-09-30 0001471781 GTCH:TokenizeholdingsinVisionWaveMember GTCH:GBTTokenizeCorpMember 2025-01-01 2025-09-30 0001471781 GTCH:TokenizeholdingsinVisionWaveMember GTCH:GBTTechnologiesIncMember 2025-01-01 2025-09-30 0001471781 us-gaap:FairValueInputsLevel1Member 2024-12-31 0001471781 us-gaap:FairValueInputsLevel2Member 2024-12-31 0001471781 us-gaap:FairValueInputsLevel3Member 2024-12-31 0001471781 us-gaap:FairValueInputsLevel1Member 2025-09-30 0001471781 us-gaap:FairValueInputsLevel2Member 2025-09-30 0001471781 us-gaap:FairValueInputsLevel3Member 2025-09-30 0001471781 us-gaap:CommonStockMember 2025-01-01 2025-09-30 0001471781 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001471781 us-gaap:SeriesBPreferredStockMember 2025-01-01 2025-09-30 0001471781 us-gaap:SeriesBPreferredStockMember 2024-01-01 2024-12-31 0001471781 us-gaap:SeriesCPreferredStockMember 2025-01-01 2025-09-30 0001471781 us-gaap:SeriesCPreferredStockMember 2024-01-01 2024-12-31 0001471781 us-gaap:SeriesHPreferredStockMember 2025-01-01 2025-09-30 0001471781 us-gaap:SeriesHPreferredStockMember 2024-01-01 2024-12-31 0001471781 GTCH:SeriesIPreferredStockMember 2025-01-01 2025-09-30 0001471781 GTCH:SeriesIPreferredStockMember 2024-01-01 2024-12-31 0001471781 us-gaap:WarrantMember 2025-01-01 2025-09-30 0001471781 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001471781 GTCH:ConvertibleNotesMember 2025-01-01 2025-09-30 0001471781 GTCH:ConvertibleNotesMember 2024-01-01 2024-12-31 0001471781 2024-01-01 2024-12-31 0001471781 GTCH:AVAIMember 2025-09-30 0001471781 GTCH:AVAIMember 2024-12-31 0001471781 GTCH:MetAlertIncsMember 2025-09-30 0001471781 GTCH:MetAlertIncsMember 2024-12-31 0001471781 GTCH:GBTTokenizeCorpMember 2023-04-03 0001471781 GTCH:TrendInnovationHoldingsIncMember GTCH:AssetPurchaseAgreementMember 2023-04-02 2023-04-03 0001471781 GTCH:GBTTokenizeCorpMember 2024-06-04 0001471781 GTCH:VisionWaveTechnologiesIncMember 2024-06-04 0001471781 GTCH:GBTTokenizeCorpMember 2024-06-03 2024-06-04 0001471781 GTCH:GBTTokenizeCorpMember 2024-06-29 2024-07-02 0001471781 GTCH:GBTTokenizeCorpMember 2024-01-01 2024-12-31 0001471781 GTCH:TrendInnovationHoldingsIncMember 2025-09-30 0001471781 GTCH:TrendInnovationHoldingsIncMember 2024-12-31 0001471781 GTCH:GTXAgreementMember 2022-04-10 2022-04-12 0001471781 GTCH:GBTTokenizeMember 2022-04-10 2022-04-12 0001471781 GTCH:GTXAgreementMember 2022-01-01 2022-12-31 0001471781 GTCH:GTXAgreementMember 2022-04-12 0001471781 GTCH:GTXAgreementMember 2024-12-31 0001471781 GTCH:GBTTokenizeMetAlertMember 2022-09-29 2022-09-30 0001471781 GTCH:PromissoryNoteMember 2022-09-29 2022-09-30 0001471781 GTCH:PromissoryNoteMember 2024-12-31 0001471781 GTCH:MetAlertIncMember 2025-09-30 0001471781 GTCH:MetAlertIncMember 2024-12-31 0001471781 GTCH:GBTSharesMember 2020-03-05 2020-03-06 0001471781 2020-03-06 0001471781 GTCH:StanleyHillsLLCMember 2021-12-31 0001471781 GTCH:TokenizeAgreementMember 2021-05-28 0001471781 GTCH:TokenizeAgreementMember 2021-05-27 2021-05-28 0001471781 2020-06-30 0001471781 2021-12-31 0001471781 GTCH:TokenizeAgreementMember 2025-09-30 0001471781 GTCH:TokenizeAgreementMember 2025-01-01 2025-09-30 0001471781 GTCH:TokenizeAgreementMember GTCH:SeriesIPreferredStockMember 2025-09-30 0001471781 GTCH:TokenizeAgreementMember GTCH:SeriesIPreferredStockMember 2025-01-01 2025-09-30 0001471781 GTCH:SeriesIPreferredStockMember 2025-09-30 0001471781 GTCH:GBTTokenizeMember 2025-09-30 0001471781 GTCH:VisionWaveMember 2024-03-19 2024-03-20 0001471781 GTCH:Igor1CorpMember 2025-09-30 0001471781 GTCH:Igor1CorpMember 2024-12-31 0001471781 GTCH:GlenEagleMember 2025-09-30 0001471781 GTCH:GlenEagleMember 2024-12-31 0001471781 GTCH:GBTTechnologiesMember us-gaap:SeriesHPreferredStockMember 2025-01-01 2025-09-30 0001471781 GTCH:GBTTechnologiesMember us-gaap:SeriesHPreferredStockMember 2025-09-30 0001471781 GTCH:GBTTechnologiesMember 2021-05-17 2021-05-19 0001471781 2021-01-01 2021-12-31 0001471781 2024-06-29 2024-07-02 0001471781 GTCH:GlenEaglesAcquisitionLPMember 2025-01-01 2025-09-30 0001471781 GTCH:GlenEaglesAcquisitionLPMember 2023-01-24 0001471781 GTCH:GlenEaglesAcquisitionLPMember 2023-01-23 2023-01-24 0001471781 GTCH:GlenEaglesAcquisitionLPMember 2025-09-30 0001471781 GTCH:GlenEaglesAcquisitionLPMember 2024-12-31 0001471781 GTCH:SBALoanMember 2025-09-30 0001471781 GTCH:SBALoanMember 2024-12-31 0001471781 GTCH:EIDLMember GTCH:SBALoanMember 2020-06-21 2020-06-22 0001471781 GTCH:SBALoanMember 2021-10-01 0001471781 GTCH:SBALoanMember 2022-03-17 0001471781 GTCH:SBALoanMember 2021-10-04 2021-10-05 0001471781 GTCH:StanleyHillsLLCMember 2019-05-03 2019-12-31 0001471781 GTCH:StanleyHillsLLCMember 2020-02-26 0001471781 GTCH:StanleyHillsLLCMember 2020-02-25 2020-02-26 0001471781 GTCH:StanleyHillsLLCMember 2021-01-01 2021-12-31 0001471781 us-gaap:ConvertibleDebtMember GTCH:StanleyHillsLLCMember 2021-12-31 0001471781 GTCH:StanleyHillsLLCMember 2023-01-02 0001471781 GTCH:StanleyHillsLLCMember 2023-01-01 2023-01-02 0001471781 GTCH:StanleyHillsLLCMember 2025-01-01 2025-09-30 0001471781 GTCH:StanleyHillsLLCMember 2023-10-01 2024-09-30 0001471781 GTCH:StanleyHillsLLCMember 2024-01-01 2024-12-31 0001471781 GTCH:StanleyHillsLLCMember 2025-09-30 0001471781 GTCH:StanleyHillsLLCMember 2024-12-31 0001471781 GTCH:AlphaEdaMember 2025-09-30 0001471781 GTCH:AlphaEdaMember 2024-12-31 0001471781 GTCH:AlphaEdaMember 2025-09-30 0001471781 GTCH:AlphaEdaMember 2024-12-31 0001471781 2022-07-07 0001471781 GTCH:BoardOfDirectorsMember 2025-01-01 2025-09-30 0001471781 2023-10-12 0001471781 GTCH:AltcorpMember us-gaap:SeriesHPreferredStockMember 2019-06-16 2019-06-17 0001471781 GTCH:AltcorpMember us-gaap:SeriesHPreferredStockMember 2019-06-17 0001471781 GTCH:GBTMember GTCH:SeriesIPreferredStockMember 2023-07-19 2023-07-20 0001471781 GTCH:GBTMember GTCH:SeriesIPreferredStockMember 2023-07-20 0001471781 GTCH:SharesToBeCancelledMember 2025-09-30 0001471781 GTCH:SharesToBeCancelledMember 2024-12-31 0001471781 GTCH:VisionWaveHoldingsMember 2024-03-19 2024-03-20 0001471781 GTCH:TokenizeMember 2024-03-19 2024-03-20 0001471781 GTCH:TokenizeholdingsinVisionWaveOneMember 2025-01-01 2025-09-30 0001471781 GTCH:TokenizeholdingsinVisionWaveOneMember GTCH:GBTTokenizeCorpMember 2025-01-01 2025-09-30 0001471781 GTCH:TokenizeholdingsinVisionWaveOneMember GTCH:GBTTechnologiesIncMember 2025-01-01 2025-09-30 0001471781 GTCH:TokenizeholdingsinVisionWaveTwoMember 2025-01-01 2025-09-30 0001471781 GTCH:GBTTokenizeCorpMember GTCH:TokenizeholdingsinVisionWaveTwoMember 2025-01-01 2025-09-30 0001471781 GTCH:GBTTechnologiesIncMember GTCH:TokenizeholdingsinVisionWaveTwoMember 2025-01-01 2025-09-30 iso4217:USD xbrli:shares iso4217:USD xbrli:shares xbrli:pure

United States

Securities and Exchange Commission

Washington, D.C. 20549

Form 10-Q

(Mark One)
☒	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2025

☐	TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commissions file number: 000-54530

GBT TECHNOLOGIES INC.

(Exact name of registrant as specified in its charter)

Nevada	27-0603137
State or other jurisdiction of	I.R.S. Employer Identification Number
incorporation or organization

8557 N West Knoll Dr. West Hollywood CA 90069

(Address of principal executive offices)

Issuer ’s telephone number: 323-207-8566

Securities registered pursuant to Section 12(b) of the Act: Not applicable.

Title of each class	Trading Symbol	Name of each exchange on which registered
Not applicable.

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ ☐ No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐

Non-accelerated filer ☒	Smaller reporting company ☒	Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of Exchange Act). Yes ☐ No ☒

State the number of shares outstanding of each of the issuer’s classes of common equity, as of the latest practicable date:

Common Stock, $0.00001 par value	18,492,870,775 Common Shares
(Class)	(Outstanding at November 14, 2025)

GBT TECHNOLOGIES INC.

TABLE OF CONTENTS

PART I.	Financial Information	Page

Item 1.	Condensed Consolidated Financial Statements	2

	Condensed Consolidated Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024	2

	Condensed Consolidated Statements of Operations for the three and nine months ended September, 2025 and 2024 (Unaudited)	3

	Condensed Consolidated Statements of Stockholder’s Deficit for the three and nine months ended September 30, 2025 and 2024 (Unaudited)	4

	Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 (Unaudited)	5

	Notes to Condensed Consolidated Financial Statements (Unaudited)	6

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	22

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	24

Item 4.	Controls and Procedures	24

PART II.	Other Information	26

Signatures		36

Item 1: Condensed consolidated financial statements


GBT TECHNOLOGIES INC.
CONDENSED CONSOLIDATED BALANCE SHEETS

ASSETS	September30, 2025			December 31, 2024
	(Unaudited)			(Audited)
Current Assets:

Cash	$	813		$	125

Marketable securities		6,277			8,462

Total current assets		7,090			8,587

Total assets	$	7,090		$	8,587

LIABILITIES AND STOCKHOLDERS’ DEFICIT

Current Liabilities:

Accounts payable and accrued expenses	$	1,388,271		$	973,706

Accounts Payable and accrued expenses - related party		3,126,726			3,126,694

Convertible notes payable, current, net of discount		5,193,411			5,110,911

Convertible notes payable, related party, net of discount		474,599			491,395

Loan payable, current		106,260			106,260

Notes payable, related party		140,000			140,000

Total current liabilities		10,429,267			9,948,966

Non-Current Liabilities:

Loan payable, noncurrent		243,740			243,740

Total noncurrent liabilities		243,740			243,740

Total liabilities		10,673,007			10,192,706

Stockholders’ Deficit:
Series B Preferred stock, $0.00001 par value; 20,000,000 shares authorized; 45,000 and 45,000 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively		—			—
Series C Preferred stock, $0.00001 par value; 10,000 shares authorized; 700 and 700 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively		—			—
Series H Preferred stock, $0.00001 par value ($500 stated value); 40,000 shares authorized; 20,000 and 20,000 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively		—			—
Series I Preferred stock, $0.00001 par value ($350 stated value); 1,000 shares authorized; 1,000 and 1,000 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively		—			—
Common stock, $0.00001 par value; 30,000,000,000 shares authorized; 18,492,870,775 and 16,813,229,180 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively		184,929			168,133
Treasury stock, at cost; 8 shares at September 30, 2025 and December 31, 2024, respectively		(11,059	)		(11,059	)

Shares to be cancelled		(632,000	)		(632,000	)

Stock loan receivable		(7,610,147	)		(7,610,147	)

Additional paid in capital		294,255,052			294,255,052

Accumulated deficit		(295,774,377	)		(295,278,233	)

Total stockholders’ deficit		(9,587,602	)		(9,108,254	)

Non-Controlling Interest		(1,078,315	)		(1,075,865	)
Total stockholders’ deficit attributable to GBT Technologies, Inc.		(10,665,917	)		(10,184,119	)

Total liabilities and stockholders’ deficit	$	7,090		$	8,587

The accompanying footnotes are an integral part of the unaudited condensed consolidated financial statements.

GBT TECHNOLOGIES INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS


	For the Three Months Ended September 30,						For the Nine Months Ended Sept 30,
	2025			2024			2025			2024
Operating expenses:
General and administrative expenses	$	2,932		$	18,120		$	11,853		$	24,588
Marketing expenses		—			57,672			—			147,912
Professional expenses		75,168			122,815			183,418			360,815
Total operating expenses		78,100			198,607			195,271			533,315

Loss from operations		(78,100	)		(198,607	)		(195,271	)		(533,315	)

Other income (expense):
Amortization of debt discount		—			(2,656	)		—			(46,003	)
Change in fair value of derivative liability		—			4,004,405			—			12,755,202
Interest expense and financing costs		(101,824	)		(175,962	)		(301,138	)		(322,560	)
Loss from Investment -Equity Method		—			(10,000	)		—			(10,000	)
Change in fair value of marketable securities		(716	)		(63	)		(2,185	)		(732	)
Gain from Debt Settlement					2,658,977						2,658,977
Total other income (expense)		(102,540	)		6,474,701			(303,323	)		15,034,884

Income (loss) before income taxes		(180,640	)		6,276,094			(498,594	)		14,501,569

Income tax expense		—			—			—			—

Income (loss) from continuing operations		(180,640	)		6,276,094			(498,594	)		14,501,569

Net income (loss)	$	(180,640	)	$	6,276,094		$	(498,594	)	$	14,501,569

Less: net (loss) income attributable to the noncontrolling interest		(484	)		(7,523	)		(2,450	)		(10,287	)

Net income (loss) attributable to GTB Technologies Inc.		(180,156	)		6,283,617			(496,144	)		14,511,856

Weighted average common shares outstanding:
Basic		18,492,870,775			16,813,229,180			17,449,269,931			16,261,212,589
Diluted		637,498,005,791			27,631,580,912			637,498,005,791			27,079,564,321
Net loss per share:
Basic	$	(0.00	)	$	0.00		$	(0.00	)	$	0.00
Diluted		(0.00	)		0.00			(0.00	)		0.00

The accompanying footnotes are an integral part of the unaudited condensed consolidated financial statements.

GBT TECHNOLOGIES INC.

CONDENSED CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

(Unaudited)


	Series B Convertible				Series C Convertible				Series H Convertible				Series I Convertible
	Preferred Stock				Preferred Stock				Preferred Stock				Preferred Stock				Common Stock				Treasury Stock					Share to be Cancelled					Stock Loan			Additional Paid-in			Accumulated			Noncontrolling			Total Stockholders'
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount			Shares		Amount			Receivable			Capital			Deficit			Interest			Deficit
Balance, December 31, 2023		45,000	$	—		700	$	—		20,000	$	—		1,000	$	—		10,253,695,062	$	102,538		8	$	(11,059	)		1,032	$	(632,000	)	$	(7,610,147	)	$	293,069,829		$	(315,993,294	)	$	(1,036,249	)	$	(32,110,382	)
Common stock issued for conversions		—		—		—		—		—		—		—		—		6,559,534,118		65,596		—		—			—		—			—			491,965			—			—			557,561
Fair value of derivative liability due to conversions		—		—		—		—		—		—		—		—		—		—		—		—			—		—			—			694,919			—			—			694,919
Tokenize investment reclassification		—		—		—		—		—		—		—		—		—		—		—		—			—		—			—			(1,660	)		—			—			(1,660	)
Net income		—		—		—		—		—		—		—		—		—		—		—		—			—		—			—						7,161,989			(2,100	)		7,159,889
Balance, March 31, 2024		45,000	$	—		700	$	—		20,000	$	—		1,000	$	—		16,813,229,180	$	168,134		8	$	(11,059	)		1,032	$	(632,000	)	$	(7,610,147	)	$	294,255,053		$	(308,831,305	)	$	(1,038,349	)	$	(23,699,672	)
VisionWave investment reclassification		—		—		—		—		—		—		—		—		—		—		—		—			—		—			—			1,000			—			—		$	1,000
Net income		—		—		—		—		—		—		—		—		—		—		—		—			—		—			—			—			1,055,750			(9,254	)	$	1,046,496
Balance, June 30, 2024		45,000	$	—		700	$	—		20,000	$	—		1,000	$	—		16,813,229,180	$	168,134		8	$	(11,059	)		1,032	$	(632,000	)	$	(7,610,147	)	$	294,256,052		$	(307,775,556	)	$	(1,047,603	)	$	(22,652,180	)
Net income		—		—		—		—		—		—		—		—		—		—		—		—			—		—			—			—			6,276,094			(7,523	)	$	6,268,571
Balance, Sept 30, 2024		45,000	$	—		700	$	—		20,000	$	—		1,000	$	—		16,813,229,180	$	168,134		8	$	(11,059	)		1,032	$	(632,000	)	$	(7,610,147	)	$	294,256,052		$	(301,481,439	)	$	(1,046,536	)	$	(16,357,995	)

	Series B Convertible				Series C Convertible				Series H Convertible				Series I Convertible
	Preferred Stock				Preferred Stock				Preferred Stock				Preferred Stock				Common Stock				Treasury Stock					Share to be Cancelled					Stock Loan			Additional Paid-in		Accumulated			Noncontrolling			Total Stockholders'
	Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount		Shares		Amount			Shares		Amount			Receivable			Capital		Deficit			Interest			Deficit
Balance, December 31, 2024		45,000	$	—		700	$	—		20,000	$	—		1,000	$	—		16,813,229,180	$	168,133		8	$	(11,059	)	$	1,032	$	(632,000	)	$	(7,610,147	)	$	294,255,052	$	(295,278,233	)	$	(1,075,865	)	$	(10,184,119	)
Net income		—		—		—		—		—		—		—		—		—		—		—		—			—		—			—			—		(101,209	)		(1,191	)		(102,400	)
Balance, March 31, 2025		45,000	$	—		700	$	—		20,000	$	—		1,000	$	—		16,813,229,180	$	168,133		8	$	(11,059	)		1,032	$	(632,000	)	$	(7,610,147	)	$	294,255,052	$	(295,379,442	)	$	(1,077,056	)	$	(10,286,519	)
Common stock issued for conversions				—				—				—				—		1,679,641,595		16,796				—					—			—			—		—			—		$	16,796
Net income																																				$	(214,778	)	$	(776	)	$	(215,554	)
Balance, June 30, 2025		45,000	$	—		700	$	—		20,000	$	—		1,000	$	—		18,492,870,775		184,930		8		(11,059	)		1,032		(632,000	)		(7,610,147	)		294,255,052		(295,594,221	)		(1,077,831	)		(10,485,277	)
Net income		—		—		—		—		—		—		—		—		—		—		—		—			—		—			—			—		(180,156	)		(484	)		(180,640	)
Balance, Sept 30, 2025		45,000	$	—		700	$	—		20,000	$	—		1,000	$	—		36,985,741,550		369,860		16		(22,118	)		2,064		(1,264,000	)		(15,220,294	)		588,510,104		(295,774,377	)		(1,078,315	)		(10,665,917	)

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

GBT TECHNOLOGIES INC.

UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS


	Nine Months Ended September 30,
	2025			2024
Cash Flows From Operating Activities:
Net Income (loss)	$	(498,594	)	$	14,501,569
Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of debt discount		—			46,003
Change in fair value of derivative liability		—			(12,755,202	)
Change in fair value of market equity security		2,185			10,000
Gain on debt extinguishment		—			(2,658,977	)
Changes in operating assets and liabilities:
Accounts payable and accrued expenses		497,065			(229,102	)
Accounts payable and accrued expenses - RP		32			1,114,231
Net cash provided by (used in) operating activities		688			28,522

Cash Flows From Financing Activities:
Repayments to note payables		—			(27,546	)
Net cash (used in) provided by financing activities		—			(27,546	)

Net changes in cash		688			976

Cash, beginning of period		125			529

Cash, end of period	$	813		$	1,505

Cash paid for:
Interest	$	—		$	—
Income taxes	$	—		$	—

Supplemental non-cash investing and financing activities
Reduction in derivative liability due to conversion	$	—		$	694,919
Shares issued for conversion of convertible debt	$	16,796		$	557,560
VisionWave investment reclassification	$	—		$
Tokenize investment reclassification	$	—		$	1,660

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

GBT Technologies, Inc.

Notes to Unaudited Condensed Consolidated Financial Statements

For the Nine Months Ended September 30, 2025 and 2024 (Unaudited)

Note 1 - Organization and Basis of Presentation

Organization and Line of Business

Effective as of March 20, 2024, Tokeniz, entered into a Patent Purchase Agreement with VisionWave Technologies Inc. (“VisionWave” or “VW”) pursuant to which VisionWave agreed to acquire from Tokenize the entire right, title, and interest of certain patents and patent applications providing an intellectual property basis for a machine learning driven technology that controls radio wave transmissions, analyzes their reflections data, and constructs 2D/3D images of stationary and in motion objects (“VisionWave PPA”). The Purchase Price for the asset is $30,000,000 (the “Purchase Price”), which VisionWave will pay with shares of common stock, $0.0001 par value per share (the “Common Stock”). The Parties agree that the final Purchase Price may be adjusted and will be governed by a valuation report issued by a professional third party (“Valuation”). If the final Purchase Price per Valuation is less than $30,000,000, Tokenize has the option to cancel this Agreement. In accordance therewith, VisionWave agreed to issue and deliver to Tokenize, 1,000 shares of Common Stock (the “Shares”) representing 50% of VisionWave’s issued and outstanding shares of Common Stock, where the remainder of the 50% of VisionWave’s issued and outstanding shares of Common Stock are owned by a corporation controlled by Anat Attia. On June 4, 2024 Tokenize were issued additional 222 shares of VW for consideration of ten million Avant Technologies Inc. (“AVAI”) shares. On August 17, 2024 Tokenize, the Company. and Magic entered into agreements effective March 26, 2024 which assign the shares issued by the Company to Tokenize, 500 to GBT and 500 to Magic. Post this transaction the Company holds 500 shares and Tokenize hold 222 shares of VW. As of September 30, 2025, the Company holds 26.53% of VW’s issued and outstanding shares. Here is the breakdown of the Company and Tokenize VW’s shareholders:


Shareholder’s Name	No. Of Shares		% of Shares Held
GBT Tokenize Corp.		222		8.16	%
GBT Technologies, Inc.		500		18.37	%

On March 26, 2024, Bannix Acquisition Corp., a Delaware corporation (“Bannix”), entered into a Business Combination Agreement (the “Original Agreement”), by and among Bannix, VisionWave Technologies, Inc., a Nevada corporation (“Target”) and the shareholders of Target.

On September 6, 2024, Bannix entered into a Merger Agreement and Plan of Reorganization (the “Merger Agreement”), by and among Bannix, VisionWave Holdings, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Bannix (“VisionWave Holdings”), BNIX Merger Sub, Inc., a Delaware corporation and a direct, wholly owned subsidiary of VisionWave Holdings (“Parent Merger Sub”), BNIX VW Merger Sub, Inc., a Nevada corporation and direct, wholly owned subsidiary of VisionWave, and Target. The Merger Agreement and the transactions contemplated thereby were approved by the boards of directors of each of Bannix, VisionWave Holdings, Parent Merger Sub, Company Merger Sub, and Target.

Said Merger was closed on July 14, 2025 and the Company holdings in Visionwave Technologies been converted into holdings in VisionWave Holdings, Inc publicly traded on NASDAQ under the Ticker VWAV.

The following is the breakdown of the Company and Tokenize holdings in VisionWave Holdings post closings:


Shareholder’s Name	No. Of Shares		% of Shares Held
GBT Tokenize Corp.		897,102		6.286	%
GBT Technologies, Inc.		2,020,500		14.158	%

The unaudited consolidated financial statements are prepared by the Company, pursuant to the rules and regulations of the SEC. The information furnished herein reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management, are necessary to fairly state the Company’s financial position, the results of its operations, and cash flows for the periods presented.

Basis of Presentation

The accompanying condensed consolidated financial statements were prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”).

Note 2 – Going Concern

The accompanying condensed consolidated financial statements have been prepared assuming the Company will continue as a going concern. The Company has an accumulated deficit of $295,774,377 and has a working capital deficit of $10,422,177 as of September 30, 2025, which raises substantial doubt about its ability to continue as a going concern.

The Company’s ability to continue as a going concern is dependent upon its ability to generate profitable operations in the future and/or obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management has plans to seek additional capital through some private placement offerings of debt and equity securities. These plans, if successful, will mitigate the factors which raise substantial doubt about the Company’s ability to continue as a going concern. These CFS do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

Note 3 – Summary of Significant Accounting Policies

Use of Estimates

The preparation of condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. The Company regularly evaluates estimates and assumptions. The Company bases its estimates and assumptions on current facts, historical experience and various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the accrual of costs and expenses that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from the Company’s estimates. To the extent there are material differences between the estimates and the actual results, future results of operations will be affected. Significant estimates in the accompanying condensed consolidated financial statements include valuation of derivatives and valuation allowance on deferred tax assets.

Principles of Consolidation

The accompanying condensed consolidated financial statements include the accounts of the Company and its subsidiaries; the Company’s 50% owned subsidiary GBT Tokenize Corp. All significant intercompany transactions and balances were eliminated.

Cash Equivalents

For the purpose of the statement of cash flows, cash equivalents include time deposits, certificate of deposits, and all highly liquid debt instruments with original maturities of three months or less. As of September 30, 2025 and December 31, 2024, the Company did not have any cash equivalents.

Marketable Securities

The Company accounts for investment securities in accordance with ASC Topic 321, Investments – equity securities. Marketable equity securities are reported at FV based on quotations available on securities exchanges with any unrealized gain or loss being reported as a component of other income (expense) on the statement of operations. The portion of marketable equity security expected to be sold within 12 months of the balance sheet date is reported as a current asset. These publicly traded equity securities are valued using quoted prices and are included in Level 1.

Derivative Financial Instruments

The Company evaluates all of its agreements to determine if such instruments have derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its FV and is then re-valued at each reporting date, with changes in the FV reported in the statements of operations. For stock-based derivative financial instruments, the Company uses a weighted-average Black-Scholes-Merton option pricing model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative instrument liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement of the derivative instrument could be required within 12 months of the balance sheet date. As of September 30, 2025 and December 31, 2024, the Company had no derivative financial instrument associated with convertible notes payable due to all the conversion features were amended to fixed conversion price.

Fair Value of Financial Instruments

For certain of the Company’s financial instruments, including cash, accounts payable, accrued liabilities and short-term debt, the carrying amounts approximate their FV due to their short maturities.

FASB ASC Topic 820, Fair Value Measurements and Disclosures, requires disclosure of the FV of financial instruments held by the Company. FASB ASC Topic 825, Financial Instruments, defines FV, and establishes a three-level valuation hierarchy for disclosures of FV measurement that enhances disclosure requirements for FV measures. The carrying amounts reported in the consolidated balance sheets for receivables and current liabilities each qualify as financial instruments and are a reasonable estimate of their FV because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest. The three levels of valuation hierarchy are defined as follows:

	●	Level 1 inputs to the valuation methodology are quoted prices for identical assets or liabilities in active markets.

	●	Level 2 inputs to the valuation methodology include quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets in inactive markets, and inputs that are observable for the asset or liability, either directly or indirectly, for substantially the full term of the financial instrument.

	●	Level 3 inputs to the valuation methodology use one or more unobservable inputs which are significant to the FV measurement.

The Company analyzes all financial instruments with features of both liabilities and equity under FASB ASC Topic 480, Distinguishing Liabilities from Equity, and FASB ASC Topic 815, Derivatives and Hedging.

For certain financial instruments, the carrying amounts reported in the balance sheets for cash and current liabilities, including convertible notes payable, each qualify as a financial instrument, and are a reasonable estimate of their FV because of the short period of time between the origination of such instruments and their expected realization and their current market rate of interest.

The Company uses Level 2 inputs for its valuation methodology for derivative liabilities as their FV were determined by using the Black-Scholes-Merton pricing model based on various assumptions. The Company’s derivative liabilities are adjusted to reflect FV at each period end, with any increase or decrease in the FV being recorded in results of operations as adjustments to FV of derivatives.

At September 30, 2025 and December 31, 2024, the Company identified the following liabilities that are required to be presented on the balance sheet at FV:

Fair Value

Fair Value Measurements at

As of

December 31, 2024

Description

December 31, 2024

Using Fair Value Hierarchy

Level 1

Level 2

Level 3

Conversion feature on convertible notes

—

Fair Value

Fair Value Measurements at

As of

September 30, 2025

Description

September 30, 2025

Using Fair Value Hierarchy

Level 1

Level 2

Level 3

Conversion feature on convertible notes

—

Treasury Stock

Treasury stock is recorded at cost. The re-issuance of treasury shares is accounted for on a first in, first-out basis and any difference between the cost of treasury shares and the re-issuance proceeds are charged or credited to additional paid-in capital. The Company has 8 treasury stock from acquisitions that commenced in 2011.

Income Taxes

The Company accounts for income taxes in accordance with ASC Topic 740, Income Taxes. ASC 740 requires a company to use the asset and liability method of accounting for income taxes, whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion, or all of, the deferred tax assets will not be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.

Under ASC 740, a tax position is recognized as a benefit only if it is “more likely than not” that the tax position would be sustained in a tax examination, with a tax examination being presumed to occur. The amount recognized is the largest amount of tax benefit that is greater than 50% likely of being realized on examination. For tax positions not meeting the “more likely than not” test, no tax benefit is recorded. The Company has no material uncertain tax positions for any of the reporting periods presented and its current on all its tax filings federal and state until 2025 inclusive.

Basic and Diluted Earnings Per Share

Earnings per share is calculated in accordance with ASC Topic 260, Earnings Per Share. Basic earnings per share (“EPS”) is based on the weighted average number of common shares outstanding. Diluted EPS assumes that all dilutive securities are converted. Dilution is computed by applying the treasury stock method. Under this method, options and warrants are assumed to be exercised at the beginning of the period (or at the time of issuance, if later), and as if funds obtained thereby were used to purchase common stock at the average market price during the period. Due to the net income incurred potentially dilutive instruments would be anti-dilutive. Accordingly, diluted loss per share is the same as basic loss for all periods presented. The following potentially-dilutive shares were excluded from the shares used to calculate diluted earnings per share as their inclusion would be anti-dilutive.


	September 30, 2025		December 31, 2024
Basic outstanding common stock		18,492,870,775		16,813,229,180
Series B preferred stock		150,000		150,000
Series C preferred stock		385,000		385,000
Series H preferred stock		1,000,000		1,000,000
Series I preferred stock		10,000,000,000		10,000,000,000
Warrants		400		400
Convertible notes		609,003,599,616		579,341,100,593
Total		637,498,005,791		606,155,865,173

Management’s Evaluation of Subsequent Events

The Company evaluates events that have occurred after the balance sheet date of September 30, 2025, through the date which the condensed consolidated financial statements are issued. Based upon the review, other than described in Note 14 – Subsequent Events, the Company did not identify any recognized or non-recognized subsequent events that would have required adjustment or disclosure in the condensed consolidated financial statements.

Recent Accounting Pronouncements

In December 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-09, “Income Taxes (Topic 740): Improvements to Income Tax Disclosures”, which requires greater disaggregation of income tax disclosures related to the income tax rate reconciliation and income taxes paid and effective for fiscal years beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued. The amendments should be applied on a prospective basis although retrospective application is permitted. The Company is currently evaluating the effects of this pronouncement on its financial statements and disclosures.

Management does not believe that any recently issued, but not yet effective, accounting standards could have a material effect on the accompanying condensed consolidated financial statements. As new accounting pronouncements are issued, we will adopt those that are applicable under the circumstances.

Note 4 – Marketable Securities

Schedule of marketable securities
	September 30, 2025		December 31, 2024
Marketable Securities from AVAI.	$	6,000	$	6,000
Marketable Securities from MetAlert Inc.		277		2,462
Total Fair Value of Marketable Securities	$	6,277	$	8,462

Investment Avant – Trend Innovation Holdings, Inc- AVAI.

On April 3, 2023, GBT Tokenize Corp., a subsidiary that is owned 50% by the Company entered into an Asset Purchase Agreement (“APA”) with Trend Innovation Holdings, Inc. (“TREN”), in which the Company consented, pursuant to which Tokenize sold certain assets relating to proprietary system and method named Avant-Ai, which is a text-generation, deep learning self-training model (the “System”).

In consideration of acquiring the System, TREN is required to issue to the Seller 26,000,000 common shares of TREN (the “Shares”). The Shares will be restricted per Rule 144 as promulgated under the Securities Act of 1933, as amended (the “1933 Act”) and Seller agreed to a lock-up period of nine (9) months following closing (the “Lock Up Term”). In the event that TREN is unable to up-list to Nasdaq either through a business combination or otherwise prior to the expiration of the Lock Up Term, the Seller may request within three (3) business days of the expiration of the Lock-Up Term, that all transactions contemplated by the APA be unwound.

In addition, TREN, Seller and GBT entered into a license agreement regarding the System, granting the Seller and/or GBT a perpetual, irrevocable, non-exclusive, non-transferable license for using the System to be used in its own development, as in-house tool, where Seller or GBT may not sublicense its rights hereunder to any customer or client.

On July 18, 2023 TREN changed its name into: Avant Technologies, Inc and its ticker symbol on OTC Markets was changed into AVAI.

On June 4, 2024 Tokenize entered into Security and Exchange Agreement together with Subscription Agreement with VisionWave Technologies Inc. (“VW”), where Tokenize invested 10,000,000 of the Shares for 222 of VW, reducing the holding in the Shares to 16,000,000.

On July 1, 2024, the Company, GBT Tokenize Corp., together with Igor 1 Corp (the “Note Holder”), entered into an agreement to amend the terms of a previously issued convertible note. The amendment includes the following changes:

Reduction of Outstanding Balance: The outstanding balance of the note as of June 30, 2024, was $7,818,411.03, with a reported balance of $5,320,420. The balance was reduced by $3,000,000 through the transfer of 10,000,000 restricted shares of AVAI, resulting in a new balance of $4,818,411.03.

Fixed Conversion Price: The conversion feature of the note was amended to establish a fixed conversion price of $0.00001 per share. This conversion price will remain unaffected by any future corporate actions, including reverse splits, dividends, or other similar actions.

Conversion Limits: The note includes a maximum share issuance of 481,841,103,000 shares under the fixed conversion price and maintains a 4.99% beneficial ownership blocker.

This transaction reducing the holding in the AVAI Shares to 6,000,000 as of December 31, 2024.

As of September 30, 2025 and December 31, 2024, the marketable security had a fair value of $6,000 and $6,000, respectively.

MetAlert (prior name GTX Corp)

On April 12, 2022, GBT Tokenize Corp (“GBT Tokenize”), a Nevada corporation which the Company owns 50% of the outstanding shares of common stock, entered into a series of agreements with GTX Corp (“GTX”) and various note holders of GTX pursuant to which Tokenize acquired a convertible promissory note of GTX of $100,000 (the “GTX Notes”). In addition, GBT Tokenize acquired 76,923 (GBT acquired 5,000,000 in the original deal, where GTX to perform a corporate action of 1:65 reverse split on September 20, 2022) shares of common stock of GTX for $150,000 - in total FV of $12,538 as of December 31, 2022 based on level 1 stock price in OTC markets.

The GTX Notes bear 10% interest and 50% of the principal may be converted into shares of common stock on a one-time basis at a conversion price of $0.01 per share. The remaining 50% of the principal must be paid in cash. The closing occurred on April 12, 2022. As of December 31, 2023, the Company wrote off the 50% of the convertible principal with all unpaid interest in total of $65,613 due to the collectability issue.

GTX changed its name into Metalert Inc. on or about September 20, 2022.

On September 30, 2022, GBT Tokenize, loaned MetAlert Inc., a Nevada corporation (f/k/a GTX Corp.) (“MetAlert”) $90,000. For such loan, MetAlert provided Tokenize a promissory note of $90,000 which is due and payable together with interest of 5% upon the earlier of September 19, 2023 or when declared by Tokenize. As of December 31, 2023, the Company wrote off the entire convertible principal with all unpaid interest in total of $95,770 due to the collectability issue.

MetAlert designs, manufactures and sells various interrelated and complementary products and services in the wearable technology and IoMT (Internet of Medical Things) marketplace.

As of September 30, 2025 and December 31, 2024, the marketable security had a fair value of $277 and $2,462, respectively.

Note 5 – Impaired Investment

Investment in Joint Venture GBT Tokenize Corp

On March 6, 2020, the Company through Greenwich, entered into a Joint Venture and Territorial License Agreement (the “Tokenize Agreement”) with Tokenize-It, S.A. (“Tokenize”), which is owned by a Costa Rica Trust represented by Pablo Gonzalez (“Gonzalez”). Gonzalez also represents Gonzalez Costa Rica Trust, which holds a note in the principal amount of $10,000,000 and is also a shareholder of the Company. Under the Tokenize Agreement, the parties formed GBT Tokenize Corp., a Nevada corporation (“GBT Tokenize”). The purpose of GBT Tokenize is to develop, maintain and support source codes for its proprietary technologies including advanced mobile chip technologies, tracking, radio technologies, AI core engine, electronic design automation, mesh, games, data storage, networking, IT services, business process outsourcing development services, customer service,

technical support and quality assurance for business, customizable and dedicated inbound and outbound calls solutions, as well as digital communications processing for enterprises and startups (“Technology Portfolio”), throughout the State of California. Upon generating any revenue from the Technology Portfolio, the Joint Venture will earn the first right of refusal for other territories. The Company pledged its 50% ownership in GBT Tokenize and its 100% ownership of Greenwich to Tokenize to secure its Technology Portfolio investment. The Company shall appoint two directors and Tokenize shall appoint one director of GBT Tokenize. Tokenize shall contribute the services and resources for the development of the Technology Portfolio to GBT Tokenize. The Company shall contribute 2,000,000 shares of common stock of the Company (“GBT Shares”) to GBT Tokenize. Tokenize and the Company will each own 50% of GBT Tokenize. The shares were valued at $5,500,000.

In addition, GBT Tokenize and Gonzalez entered into a Consulting Agreement in which Gonzalez is engaged to provide services for $33,333 per month payable quarterly which may be paid in shares of common stock calculated by the amount owed divided by the Company’s 10-day VWAP. Gonzalez will provide services in connection with the development of the business as well as GBT Tokenize’s capital raising efforts. The term of the Consulting Agreement is two years. During year ended December 31, 2021, Gonzalez assigned all his accrued balances of $424,731 to Stanley Hills in a private transaction that the Company is not part to. The closing of the Tokenize Agreement occurred on March 9, 2020.

Through this Joint Venture the parties commenced development of an intelligent human vital signs’ device, which we currently refer to as the qTerm. The platform is an expansion of the existing license agreement with GBT Tokenize Corp., which provided GBT Tokenize Corp. with an exclusive territory of California to develop certain of the Company’s technology. As the nature of the platform cannot be restricted only to California, the Company’s joint venture GBT Tokenize Corp. will be compensated with additional two hundred million shares of the Company to strengthen its funding, subject to board approval. A provisional patent application for the term Medical Device was filed on March 30, 2020 with the USPTO. The application has been assigned serial number 63001564. The Joint Venture completed successfully the first prototype. There is no guarantee that the Company will be successful in researching, developing or implementing this product into the market. In order to successfully implement this concept, the Company will need to raise adequate capital to support its research and, if successfully researched, developed and granted regulatory approval, the Company would need to enter into a strategic relationship with a third party that has experience in manufacturing, selling and distributing this product. There is no guarantee that the Company will be successful in any or all of these critical steps. On May 28, 2021, the parties agreed to amend the Tokenize Agreement to expand territory granted for the Technology Portfolio under the license to GBT Tokenize to include the entire continental United States. The Company has further agreed to issue GBT Tokenize an additional 14,000,000 shares of common stock of the Company. The shares were valued at $15,400,000. At March 31, 2020, the Company evaluated the carrying amount of this joint venture investment and determined that this investment was fully impaired and as a result an impairment charge of $5,500,000 was taken. At December 31, 2021, the Company evaluated the carrying amount of this joint venture investment and determined that this investment was fully impaired and as a result an impairment charge of $15,400,000 was taken.

On July 20, 2023, the Company through its wholly owned inactive subsidiary, Greenwich International Holdings, a Costa Rica corporation (“Greenwich”), entered into an Amended and Restated Joint Venture (the “2023 Tokenize Agreement”) with Magic Internacional Argentina FC, S.L. (“Magic”) and GBT Tokenize Corp (“GBT Tokenize”).

The 2023 Tokenize Agreement restated and replaced the 2022 Tokenize Agreement. Pursuant to the 2023 Tokenize Agreement, as a result of the contribution of the Technology Portfolio by Tokenize and the subsequent contribution of services for the development of the Technology Portfolio by Tokenize and Magic, GBT Tokenize has been able to continue in operation, which has benefited the Company despite its contribution of 166 million shares of common stock valued at approximately $50,000. In order to maintain its 50% ownership interest in GBT Tokenize, the Company agreed to contribute its portfolio of intellectual property to GBT Tokenize and issue to GBT Tokenize 1,000 shares of Series I Preferred Stock (the “Series I Stock”) with a stated value of $35,000 per share which is convertible into common stock of the Company by dividing the stated value by the conversion price of $0.0035, which, if converted in full would result in the issuance of 10 billion shares of common stock of the Company. Further, the Series I Stock will vote on an as converted basis.

The Company pledged its 50% ownership in GBT Tokenize and its 100% ownership of Greenwich to Magic to secure its Technology Portfolio investment.

Effective as of March 20, 2024, Tokeniz, entered into a Patent Purchase Agreement with VisionWave Technologies Inc. (“VisionWave”) pursuant to which VisionWave agreed to acquire from Tokenize the entire right, title, and interest of certain patents and patent applications providing an intellectual property basis for a machine learning driven technology that controls radio wave transmissions, analyzes their reflections data, and constructs 2D/3D images of stationary and in motion objects (“VisionWave PPA”). The Purchase Price for the asset is $30,000,000 (the “Purchase Price”), which VisionWave will pay with shares of common stock, $0.0001 par value per share (the “Common Stock”). The Parties agree that the final Purchase Price may be adjusted and will be governed by a valuation report issued by a professional third party (“Valuation”). If the final Purchase Price per Valuation is less than $30,000,000, Tokenize has the option to cancel this Agreement. In accordance therewith, VisionWave agreed to issue and deliver to Tokenize, 1,000 shares of Common Stock (the “Shares”) representing 50% of VisionWave’s issued and outstanding shares of Common Stock, where the remainder of the 50% of VisionWave’s issued and outstanding shares of Common Stock are owned by a corporation controlled by Stanley Hills, LLC. Effective June 4, 2024 Tokenize been issued additional 222 from VisionWave for consideration of 10 million AVAI shares that been vested under VisionWave.

Although the investment was impaired, the product development is still ongoing. The carrying amount of this investment at September 30, 2025 and December 31, 2024 was $0, respectively.

Note 6 – Accounts Payable and Accrued Expenses

Accounts payable and accrued expenses at September 30, 2025 and December 31, 2024 consist of the following:


	September 30, 2025		December 31, 2024
Accounts payable	$	796,244	$	686,242
Accrued liabilities		135,000		—
Accrued interest		457,029		287,464
Total	$	1,388,273	$	973,706

Accounts payable consisted of $561,740 aged outstanding balances due to two vendors over 2 years.

The increase in accrued liabilities was due to the accrued interest of convertible notes and loan from SBA.


	September 30, 2025		December 31, 2024
Accounts payable – related parties	$	1,146,164	$	1,160,000
Accrued interest - related parties		218,159		171,408
Other payables - related parties		1,762,403		1,795,286
Total	$	3,126,726	$	3,126,694

Accounts payable – related parties consisted of approximately $1,071,164 aged outstanding balances due to two major related parties for business purpose over 2 years.

Accrued interest – related parties consisted of unpaid interest from related parties note payable as of December 31, 2024.

Other payables consisted of approximately $1,745,004 advanced payments from one of the related parties for business purposes.

Note 7 – Convertible Notes Payable, Non-related Parties

Convertible notes payable – nonrelated parties at September 30, 2025 and December 31, 2024 consist of the following:


	September 30,			December 31,
	2024			2024
Convertible note payable to Igor 1 Corp.	$	4,818,411		$	4,818,411
Convertible notes payable to Glen Eagle		375,000			292,500
Total convertible notes payable, non-related parties		5,193,411			5,110,911
Unamortized debt discount		—			—
Convertible notes payable – nonrelated parties		5,193,411			5,110,911
Less current portion		(5,193,411	)		(5,110,911	)
Convertible notes payable – nonrelated parties, long-term portion	$	—		$	—

$10,000,000 for GBT Technologies S. A. acquisition – Holder Igor 1 Corp

In accordance with the acquisition of GBT-CR the Company issued a convertible note in the principal amount of $10,000,000. The convertible note bears interest of 6% and is payable at maturity on December 31, 2021. At the election of the holder, the convertible note can be converted into a maximum of 20,000 shares of Series H Preferred Stock. Each share of Series H Preferred Stock is convertible, at the option of the holder but subject to the Company increasing its authorized shares of common stock, into such number of shares of common stock of the Company as determined by dividing the Stated Value ($500 per share) by the conversion price ($500 per share). This convertible note may convert into shares of the Company’s common stock at a conversion price equal to 85% of the lowest trading price with a 20-day lookback immediately preceding the date of conversion and therefore recorded as derivative liability.

On May 19, 2021, the Company, Gonzalez, GBT-CR and IGOR 1 Corp entered into a Mutual Release and Settlement Agreement and Irrevocable Assignment of outstanding balance plus accrued interest (the “Gonzalez Agreement”). Pursuant to the Gonzalez Agreement, without any party admission of liability and to avoid litigation, the parties had agreed to (i) extend the GBT convertible note maturity date to December 31, 2022, (ii) amend the GBT convertible note terms to include a beneficial ownership blocker of 4.99% and a modified conversion feature to the GBT convertible note with 15% discount to the market price during the 20 trading day period ending on the latest complete trading day prior to the conversion date and (iii) provided for an assignment of the GBT convertible note by Gonzalez to a third party. As a result of the change in terms of this convertible note, the Company took a charge related to the modification of debt of $13,777,480 during the year ended December 31, 2021. This convertible note is recorded as derivative liability because of the discounted price on conversion.

During the period ended September 30, 2024, IGOR 1 converted $195,500 of the convertible note into 2,300,000,000 shares of the Company’s common stock.

On July 1, 2024, the Company entered into an amendment by and between the Company and IGOR 1 to (1) The Company agrees to transfer 10,000,000 restricted shares of AVAI to the note holder valued at $3,000,000 on the effective date; (2) Amended the conversion price to a fixed price of $0.00001 per share; (3) The total outstanding principal balance including accrued interest shall be adjusted to $4,818,411; and (4) The maximum number of shares that may be issued under the fixed conversion price remain subject to the terms set forth in the original note and shall not be adjusted further by this amendment. The maximum number of shares that can be issued is 481,841,103,000. The Company recognized gain on debt modification of $1,638,163 on the effective date.

As of September 30, 2025 and December 31, 2024, the note had an outstanding balance of $4,818,411 and $4,818,411, and accrued interest of $361,974.89 and $145,740, respectively.

Glen Eagle

The Company entered into a series of loan arrangements with Glen Eagles Acquisition LP pursuant to which it received $512,500 in loans (the “Debt”) from August 2021 up to September 2022. The original funded amount of $457,500 included convertible feature into shares of the Company’s common stock at a conversion price equal to 85% of the lowest trading price during the 20-day period preceding the date of conversion.

In order to include a convertible feature for the $55,000 which was not covered by convertible feature, on January 24, 2023, the Company issued a consolidated convertible promissory note to Glen Eagles Acquisition LP in the principal amount of $512,500, which include all prior convertible notes with addition of the $55,000 straight note. The convertible promissory note bears interest of 10% and is payable at maturity on December 31, 2023. Glen Eagles Acquisition LP may convert the consolidated convertible Note into shares of the Company’s common stock at a conversion price equal to 85% of the lowest trading price during the 20-day period preceding the date of conversion. The Company recorded a loss on debt extinguishment of $92,737 at the issuance date.

During the period ended September 30, 2024, Glen Eagle converted $170,000 of the convertible note into 2,000,000,000 shares of the Company’s common stock.

On December 31, 2024, the Company entered into an amendment by and between the Company and Glen Eagle to (1) Amended the conversion price to a fixed price of $0.00001 per share; (2) The total outstanding principal balance including accrued interest shall be adjusted to $349,157; and (4) The maximum number of shares that may be issued under the fixed conversion price remain subject to the terms set forth in the original note and shall not be adjusted further by this amendment. The maximum number of share that can be issued is 37,500,000,000. The Company recognized gain on debt modification of $156,833 on the effective date.

As of September 30, 2025 and December 31, 2024, the consolidated convertible note had an outstanding balance of $375,000 and $295,000 and an accrued interest of $26,014 and $82,500, respectively.

Note 8 – Loan Payable, Non-related Parties

Loan payable, non-related parties at September 30, 2025 and December 31, 2024 consist of the following:


	September 30,			December 31,
	2025			2024
SBA loan	$	350,000			350,000
Total loan payable		350,000			350,000
Unamortized debt discount		—			—
Loan payable, net of debt discount		350,000			350,000
Less current portion		(106,260	)		(106,260	)
Loan payable, long-term portion	$	243,740		$	243,740

SBA Loan

On June 22, 2020, the Company received a loan from the Small Business Administration under the Economic Injury Disaster Loan program related to the COVID-19 relief efforts. The loan bears interest at 3.75%, requires monthly principal and interest payments of $731 after 12 months from funding and is due 30 years from the date of issuance. The monthly payments have been extended by the SBA to all EIDL borrowers with additional 12 months. Monthly payments will be commenced on or around June 16, 2022. On October 1, 2021, the Company entered an Amended Loan Authorization and Agreement with the SBA providing for the modification of the Original Note providing for monthly principal and interest payments of $1,771 after 24 months from the Original Note commencing on or around June 22, 2022. On March 17, 2022 the SBA notified it deferred the payments to all COVID-19 EIDL loans will have the first payment due extended from 24-months to 30-months from the date of the note. The Modified Note will continue to bear interest at 3.75% and is due 30 years from the date of issuance of the Original Note. The Modified Note is guaranteed by Douglas Davis, the former CEO of the Company and current consultant, as well as by GBT Tokenize Corp. The additional funding of $200,000 was received by the Company on October 5, 2021.

The current portion of principal balance of the loan at September 30, 2025 and December 31, 2024 was $106,260 and $106,260 plus accrued interest of $69,040 and $50,204, respectively. The noncurrent portion of principal balance of the note at September 30, 2025 and December 31, 2024 was $243,740 and $243,740, respectively. The Company did not make any payment on the loan and seeking hardship from the SBA for reduce payment which was not yet addressed by the SBA.

Note 9 – Related Party Transactions

Convertible notes payable – related parties at September 30, 2025 and December 31, 2024 consist of the following:


	September 30,			December 31,
	2025			2024
Convertible note payable to Stanley Hills		474,599			491,395
Unamortized debt discount		—			—
Convertible notes payable, net, related party		474,599			491,395
Less current portion		(474,599	)		(491,395	)
Convertible notes payable, net, related party, long-term portion	$	—		$	—

Stanley Hills LLC

The Company entered into a series of loan agreements with Stanley Hills LLC (“Stanley”) pursuant to which it received more than $1,000,000 in loans (the “Debt”) from May 2019 up to December 2019. On February 26, 2020, in order to induce Stanley to continue to provide funding, the Company and Stanley entered into a letter agreement providing that the current note payable balance due to Stanley of $1,214,900 may be converted into shares of common stock of the Company at a conversion price equal to 85% multiplied by the lowest one trading price for the common stock during the 20-trading day period ending on the latest complete trading day prior to the conversion date. Since the conversion price will vary based on the Company’s stock price, the beneficial conversion feature associated with this note is accounted for as a derivative liability. Stanley had agreed to restrict its ability to convert the Debt and receive shares of common stock such that the number of shares of common stock held by it and its affiliates after such conversion or exercise does not exceed 4.99% of the then issued and outstanding shares of common stock. During the year ended December 31, 2021, Stanley converted $1,231,466 of its convertible note plus interest into 4,420,758 shares of the Company’s common stock, and during the year ended December 31, 2021, Stanley loaned the Company an additional $325,000. Also, during the year ended December 31, 2021, the Company transferred the SURG shares received as repayment of $800,000 of this convertible note and also converted $126,003 of accrued interest into the principal balance. During the year ended December 31, 2021, Gonzalez assigned all his accrued balances of $424,731 to Stanley in a private transaction that the Company is not part to (See Note 10). On January 2, 2023, the Company issued a convertible promissory note to Stanley for its credit balances in the principal amount of $750,000. The convertible promissory note bears interest of 10% and is payable at maturity on September 30, 2024. Stanley may convert the consolidated convertible Note into shares of the Company’s common stock at a conversion price equal to 85% of the lowest trading price during the 20-day period preceding the date of conversion. The Company recorded a gain on debt extinguishment of $408,034 at the issuance date.

During the period ended September 30, 2024, Stanley Hills converted $170,000 of the convertible note into 2,000,000,000 shares of the Company’s common stock.

On December 31, 2024, the Company entered into an amendment by and between the Company and Stanley Hills LLC to (1) Extended the maturity date of the note to December 31, 2025; (2) Amended the conversion price to a fixed price of $0.00001 per share; (3) The total outstanding principal balance including accrued interest shall be adjusted to $600,000; and (4) The maximum number of shares that may be issued under the fixed conversion price remain subject to the terms set forth in the original note and shall not be adjusted further by this amendment. The maximum number of shares that can be issued is 60,000,000,000. The Company recognized gain on debt modification of $250,054 on the effective date.

During the period ended September 30, 2025, Stanley Hills converted $16,796 of the convertible note into 1,679,641,595 shares of the Company’s common stock.

As of September 30, 2025 and December 31, 2024, the principal balance of Stanley debt was $474,599 and $491,395 respectively. The unpaid interest of the Stanley debt at September 30, 2025 and December 31, 2024 was $144,884 and $108,605, respectively.

Notes payable, related party at September 30, 2025 and December 31, 2024 consist of the following:


	September 30,			December 31,
	2025			2024
Alpha Eda Note payable	$	140,000		$	140,000
Total notes payable, related party		140,000			140,000
Unamortized debt discount		—			—
Notes payable, net, related party		140,000			140,000
Less current portion		(140,000	)		(140,000	)
Notes payable, net, related party, long-term portion	$	—		$	—

Alpha Eda

On November 15, 2020, the Company issued a promissory note to Alpha Eda, LLC (“Alpha”), a related party for $140,000. The note accrues interest at 10%, is unsecured and was due on September 30, 2021. On December 31, 2024 Alpha and the Company extended the note maturity to December 31, 2025. The balance of the note at September 30, 2025 and December 31, 2024 was $140,000 and $140,000 plus accrued interest of $73,274 and $62,803, respectively.

Note 10 - Stockholders’ Equity

Common Stock

In July 7, 2022 the Company filed a preliminary information statement to the stockholders of record (the “Record Date”) in connection with certain actions to be taken by the written consent by stockholders holding a majority of the voting stock of the Company, dated as of June 28, 2022.

●

To amend the Company’s Articles of Incorporation, (the “Articles of Incorporation”) to increase the number of authorized shares of common stock, par value $0.00001 per share (the “Common Stock”), of the Company from 2,000,000,000 shares to 10,000,000,000 shares. This action concluded on August 11, 2022.

●

(i) authorize the Company’s Board of Directors to effect, in its sole discretion, a reverse stock split of the Common Stock in a ratio of up to 1-for-500 (the “Reverse Stock Split”), and (ii) authorize the filing of an amendment to the Company’s Articles of Incorporation to implement the Reverse Stock Split and any other action deemed necessary to effectuate the Reverse Stock Split, without further approval or authorization of stockholders, at any time prior to December 31, 2023. This action was not commenced yet by the Company’s board.

On October 12, 2023, the Company amended its articles of incorporation to increase its authorized shares of common stock to 30,000,000,000 (the “Increase Amendment”). The Increase Amendment was approved by the board of directors as well as the shareholders holding in excess of a majority of the issued and outstanding voting shares of the Company.

During the year ended December 31, 2024, the Company had the following transactions in its common stock:

●

Of 6,559,534,118 shares issued for the conversion of convertible notes of $555,680 and accrued interest of $1,880.

During the nine months ended September 30, 2025, the Company had the following transactions in its common stock:

●

Of 1,679,641,595 shares issued for the conversion of convertible notes of $16,796.

As of September 30, 2025 and December 31, 2024, there were 18,492,870,775 and 16,813,229,180 shares of common stock issued and outstanding, respectively.

Series B Preferred Shares

The Series B Preferred Stock has a stated value of $100 per share and is convertible into the Company’s common stock at a conversion price of $30 per share representing 3,000 posts reverse split common shares. Furthermore, the Series B Preferred Stock votes on an as converted basis and carries standard anti-dilution rights. These rights were subsequently removed, except in cases of stock dividends or splits.

As of September 30, 2025 and December 31, 2024, there were 45,000 Series B Preferred Shares outstanding, respectively.

Series C Preferred Shares

Each share of Series C Preferred Stock is convertible, at the option of GV, into such number of shares of common stock of the Company as determined by dividing the Stated Value (as defined below) by the Conversion Price (as defined below). The Conversion Price for each share is equal to a 50% discount to the average of the lowest three lowest closing bid prices of the Company’s common stock during the 10-day trading period prior to the conversion with a minimum conversion price of $0.02. The stated value is $11 per share (the “Stated Value”). The Series C Preferred Stock has no liquidation preference, does not pay dividends and the holder of Series C Preferred Stock shall be entitled to one vote for each share of common stock that the Series C Preferred Stock shall be convertible into. GV has contractually agreed to restrict its ability to convert the Series C Preferred Stock and receive shares of the Company’s common stock such that the number of shares of the Company’s common stock held by it and its affiliates after such conversion does not exceed 4.9% of the then issued and outstanding shares of the Company’s common stock.

The issuance of the Series C Preferred Stock was made in reliance upon exemptions from registration pursuant to Section 4(a)(2) under the Securities Act of 1933 and Rule 506 promulgated under Regulation D thereunder. GV is an accredited investor as defined in Rule 501 of Regulation D promulgated under the Securities Act of 1933.

At September 30, 2025 and December 31, 2024, GV owns 700 Series C Preferred Shares, respectively.

Series H Preferred Shares

On June 17, 2019, the Company, AltCorp Trading LLC, a Costa Rica company and a wholly-owned subsidiary of the Company (“AltCorp”), GBT Technologies, S.A., a Costa Rica company (“GBT-CR”) and Pablo Gonzalez, a shareholder’s representative of GBT-CR (“Gonzalez”), entered into and closed an Exchange Agreement (the “GBT Exchange Agreement”) pursuant to which the parties exchanged certain securities. In accordance with the Exchange Agreement, AltCorp acquired 625,000 shares of GBT-CR representing 25% of its issued and outstanding shares of common stock from Gonzalez for the issuance of 20,000 shares of Series H Convertible Preferred Stock of the Company and a Convertible Note of $10,000,000 issued by the Company (the “Gopher Convertible Note”) as well as additional consideration. The Gopher Convertible Note bears interest of 6% and is payable at maturity on December 31, 2021. At the election of Gonzalez, the Gopher Convertible Note can be converted into a maximum of 20,000 shares of Series H Preferred Stock. Each share of Series H Preferred Stock is convertible,

at the option of the holder but subject to the Company increasing its authorized shares of common stock, into such number of shares of common stock of the Company as determined by dividing the Stated Value ($500 per share) by the conversion price ($10 per share). The Series H Preferred Stock has no liquidation preference, does not pay dividends and the holder of Series H Preferred Stock shall be entitled to one vote for each share of common stock that the Series H Preferred Stock may be convertible into.

As of September 30, 2025 and December 31, 2024, there are 20,000 shares of Series H Preferred Shares outstanding, respectively.

Series I Preferred Shares

On July 20, 2023, the Company through its wholly owned subsidiary, Greenwich International Holdings, a Costa Rica corporation (“Greenwich”), entered into an Amended and Restated Joint Venture (the “2023 Tokenize Agreement”) with Magic and GBT Tokenize. The 2023 Tokenize Agreement restated and replaced the 2022 Tokenize Agreement. Pursuant to the 2023 Tokenize Agreement, as a result of the contribution of the Technology Portfolio by Tokenize and the subsequent contribution of services for the development of the Technology Portfolio by Tokenize and Magic, GBT Tokenize has been able to continue in operation, which has benefited the Company despite its contribution of 166 million shares of common stock valued at approximately $50,000.

In order to maintain its 50% ownership interest in GBT Tokenize, the Company agreed to contribute its portfolio of intellectual property to GBT Tokenize and issue to GBT Tokenize 1,000 shares of Series I Preferred Stock (the “Series I Stock”) with a stated value of $35,000 per share which is convertible into common stock of the Company by dividing the stated value by the conversion price of $0.0035, which, if converted in full would result in the issuance of 10 billion shares of common stock of the Company. Further, the Series I Stock will vote on an as converted basis.

As of September 30, 2025 and December 31, 2024, there are 1,000 shares of Series I Preferred Shares outstanding, respectively.

Treasury Shares

On April 25, 2011, the Company issued a press release announcing that its Board of Directors approved a share repurchase program. Under the program, the Company is authorized to purchase up to 200-post-split (1,000,000 pre-split) of its shares of common stock in open market transactions at the discretion of management. All stock repurchases will be subject to the requirements of Rule 10b-18 under the Securities Exchange Act of 1934, as amended and other rules that govern such purchases.

As of September 30, 2025 and December 31, 2024, the Company has 8 treasury stock on a cost basis of $11,059, respectively.

As of September 30, 2025 and December 31, 2024, the Company has 1,032 shares to be cancelled on a cost basis of $632,000, respectively.

Warrants

The following is a summary of warrant activity.

Schedule of warrant activity
					Weighted
			Weighted		Average
			Average		Remaining		Aggregate
	Warrants		Exercise		Contractual		Intrinsic
	Outstanding		Price		Life		Value
Outstanding, December 31, 2024		400	$	1,595		0.02	$	—
Granted		—		—
Forfeited		—		—
Exercised		—		—
Outstanding, September 30, 2025		400	$	1,595		0.02	$	—
Exercisable, September 30, 2025		400	$	1,595		0.02	$	—

Note 11 - Legal Proceedings

From time to time, the Company may be involved in various litigation matters, which arise in the ordinary course of business. There is currently no litigation that management believes will have a material impact on the financial position of the Company.

Note 12 - Contingencies

Potential IP’s Sale

The Purchase Price for the asset is $30,000,000 (the “Purchase Price”), which VisionWave will pay with shares of common stock, $0.0001 par value per share (the “Common Stock”). The Parties agree that the final Purchase Price may be adjusted and will be governed by a valuation report issued by a professional third party (“Valuation”). If the final Purchase Price per Valuation is less than $30,000,000, Tokenize has the option to cancel this Agreement. In accordance therewith, VisionWave agreed to issue and deliver to Tokenize, 1,000 shares of Common Stock (the “Shares”) representing 50% of VisionWave’s issued and outstanding shares of Common Stock, where the remainder of the 50% of VisionWave’s issued and outstanding shares of Common Stock are owned by a corporation controlled by Stanley Hills. Effective June 4, 2024 Tokenize been issued additional 222 shares from VisionWave for consideration of 10 million AVAI shares that been vested under VisionWave name.

Said Merger was closed on July 14, 2025 and the Company holdings in Visionwave Technologies been converted into holdings in VisionWave Holdings, Inc publicly traded on NASDAQ under the Ticker VWAV.

. Here is the breakdown of the Company and Tokenize holdings in VisionWave Holdings post closings:

Schedule of shareholder’s
Shareholder’s Name	No. Of Shares		% of Shares Held
GBT Tokenize Corp.		897,102		6.286	%
GBT Technologies, Inc.		2,020,500		14.158	%

Note 13 – Concentrations

Liquidity risk

The Company has an accumulated deficit of $295,774,377 and has a working capital deficit of $10,422,177 as of September 30, 2025, which raises substantial doubt about its ability to continue as a going concern as the Company does not have sufficient funds to discharge its current liabilities.

Note 14 - Subsequent Events

The Company has evaluated its operations subsequent to September 30, 2025 to the date these unaudited consolidated financial statements were available to be issued and determined the following subsequent events and transactions required disclosure in these consolidated financial statements.

The Merger Between Bannix and VisionWave was closed on July 14, 2025 and the Company holdings in Visionwave Technologies been converted into holdings in VisionWave Holdings, Inc publicly traded on NASDAQ under the Ticker VWAV.

Here is the breakdown of the Company and Tokenize holdings in VisionWave Holdings post closings:

Schedule of Shareholders
Shareholder’s Name	No. Of Shares		% of Shares Held
GBT Tokenize Corp.		897,102		6.286	%
GBT Technologies, Inc.		2,020,500		14.158	%

On July 21, 2025, Danny Rittman notified the Company of his resignation from his position as Chief Technology Officer and as a member of the Board of Directors effective immediately. Dr. Rittman’s resignation was due to his need to commit to his role a Chief Technology Officer of VisionWave Holdings, Inc. and was not the result of any disagreement with the Company on any matter relating to its operations, policies, or practices.

Perpetual Exclusive Patent License Agreement

On November 12, 2025, after the balance-sheet date but prior to the issuance of these financial statements, GBT Tokenize Corp., a wholly owned subsidiary of the Company (“Licensor”), entered into a Perpetual Patent License Agreement (Exclusive) with Boca Jom LLC (“Licensee”). Under the agreement, the Licensor granted the Licensee an exclusive, worldwide, perpetual, irrevocable, transferable, and sublicensable license to make, use, sell, offer for sale, import, export, and commercialize products and services covered by three United States patents and their related families:

US 11,763,062; US 11,853,682; and US 11,586,799.

In consideration for the rights granted, Licensee will pay the Licensor a running royalty of five percent (5%) of Patent-Derived Revenue, as defined in the agreement. The Licensee is required to provide quarterly royalty reports, maintain auditable records, and permit an annual royalty audit. The Licensor retains ownership of the Patent Rights and limited internal research right.

The agreement also provides:

●

Licensee has the first right to enforce the Patent Rights against infringers, at its own expense;

●

Any enforcement recoveries, net of costs, are treated as Patent-Derived Revenue;

●

Licensor may step in if Licensee elects not to pursue enforcement; and

●

Licensor may reassign prosecution or maintenance responsibilities under certain circumstances.

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATION

The following discussion should be read in conjunction with our consolidated financial statements(“CFS”) and related notes included elsewhere in this report. In addition to historical information, this discussion includes forward-looking information that involves risks and assumptions, which could cause actual results to differ materially from management’s expectations. See “Forward-Looking Statements” included in this report.

Forward-Looking Statements

This Quarterly Report on Form 10-Q contains forward-looking statements, including without limitation, statements related to our plans, strategies, objectives, expectations, intentions and adequacy of resources. Investors are cautioned that such forward-looking statements involve risks and uncertainties including without limitation the following: (i) our plans, strategies, objectives, expectations and intentions are subject to change at any time at our discretion; (ii) our plans and results of operations will be affected by our ability to manage growth; and (iii) other risks and uncertainties indicated from time to time in our filings with the Securities and Exchange Commission.

In some cases, you can identify forward-looking statements by terminology such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘could,’’ ‘‘expects,’’ ‘‘plans,’’ ‘‘intends,’’ ‘‘anticipates,’’ ‘‘believes,’’ ‘‘estimates,’’ ‘‘predicts,’’ ‘‘potential,’’ or ‘‘continue’’ or the negative of such terms or other comparable terminology. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Moreover, neither we nor any other person assumes responsibility for the accuracy and completeness of such statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. We are under no duty to update any of the forward-looking statements after the date of this Report.

This section of the report should be read together with Footnotes of the Company audited financials for the year ended December 31, 2024, the unaudited statements of operations for the three and nine months ended September 30, 2025 and 2024 are compared in the sections below.

General Overview

Organization and Line of Business

GBT Technologies Inc. (the “Company”, “GBT”, or “GTCH”) was incorporated on July 22, 2009 under the laws of the State of Nevada. The Company is targeting growing markets such as development of Internet of Things (IoT) and Artificial Intelligence (AI) enabled networking and tracking technologies, including wireless mesh network technology platform and fixed solutions, development of an intelligent human body vitals device, asset-tracking IoT, and wireless mesh networks. The Company derived revenues from (i) the provision of IT consulting services; and (ii) from the licensing of its technology. (ii) from selling electronic products through e-commerce platforms (until the period June 30, 2023 as then this operation was terminated on July 1, 2023.)

On July 20, 2023, the Company through its wholly owned subsidiary, Greenwich International Holdings, a Costa Rica corporation (“Greenwich”), entered into an Amended and Restated Joint Venture (the “2023 Tokenize Agreement”) with Magic Internacional Argentina FC, S.L. (“Magic”) and GBT Tokenize Corp (“GBT Tokenize”). GBT Tokenize has developed a vital device based on the Technology Portfolio that is ready for commercialization, as well as certain derivative technologies, which positioned GBT Tokenize to further develop or license certain code sources. On April 3, 2023, GBT Tokenize entered its first commercial transaction to date through the sale of Avant-AI! technology that has been developed by GBT Tokenize, based on the Technology Portfolio. Effective as of March 20, 2024, Tokeniz, entered into a Patent Purchase Agreement with VisionWave Technologies Inc. (“VisionWave”) pursuant to which VisionWave agreed to acquire from Tokenize the entire right, title, and interest of certain patents and patent applications providing an intellectual property basis for a machine learning driven technology that controls radio wave transmissions, analyzes their reflections data, and constructs 2D/3D images of stationary and in motion objects (“VisionWave PPA”).

The unaudited condensed financial statements (“CFS”) are prepared by the Company, pursuant to the rules and regulations of the SEC. The information furnished herein reflects all adjustments, consisting only of normal recurring adjustments, which in the opinion of management, are necessary to fairly state the Company’s financial position, the results of its operations, and cash flows for the periods presented.

Results of Operations:

Three Months Ended September 30, 2025 and 2024

A comparison of the statements of operations for the three months ended September 30, 2025 and 2024 is as follows:

	Three Months Ended September 30,						Change
	2025			2024			$			%
Operating expenses		78,100			198,607			(120,507	)		-61	%
Loss from operations		(78,100	)		(198,607	)		(120,507	)		-61	%
Other income (expenses)		(102,540	)		6,474,701			(6,577,241	)		-102	%
Income (Loss) before provision for income taxes		(180,640	)		6,276,094			(6,456,734	)		-103	%
Provision for income taxes		—			—			—			—
Net Income (Loss)	$	(180,640	)	$	6,276,094			(6,456,734	)		-103	%

Operating expenses for the three months ended September 30, 2025 were $78,100, compared to $198,607 for the same period in 2024. The decrease of $120,507 or -61% was principally due to the Company had limited cash flows to expand the business.

Other income (expense) for the three months ended September 30, 2025 was $(102,540), a decrease of $6,577,241 or 102% from income of $6,474,701 for the same period in 2024. The change is principally due to a decrease of derivative liabilities since all the converted note payables were amended to fixed conversion features in Q4 2024.

Net income (loss) for the three months ended September 30, 2025 was $(180,640) compared to $6,276,094 for the same period in 2024 due to the factors described above.

Nine Months Ended September 30, 2025 and 2024

A comparison of the statements of operations for the nine months ended September 30, 2025 and 2024 is as follows:

	Nine Months Ended September 30,						Change
	2025			2024			$			%
Operating expenses		195,271			533,315			(338,044	)		-63	%
Loss from operations		(195,271	)		(533,315	)		(338,044	)		-63	%
Other income (expenses)		(303,323	)		15,034,884			(15,338,207	)		-102	%
Income (Loss) before provision for income taxes		(498,574	)		14,501,569			(15,000,163	)		-103	%
Provision for income taxes		—			—			—			—
Net Income (Loss)	$	(498,594	)	$	14,501,569			(15,000,163	)		-103	%

Operating expenses for the nine months ended September 30, 2025 were $195,271, compared to $533,315 for the same period in 2024. The decrease of $338,044 or -63% was principally due to the Company had limited cash flows to expand the business.

Other income (expense) for the nine months ended September 30, 2025 was $(303,323), a decrease of $15,338,207 or -102% from income of $15,034,884 for the same period in 2024. The change is principally due to a decrease of derivative liabilities since all the converted note payables were amended to fixed conversion features in Q4 2024.

Net income (loss) for the nine months ended September 30, 2025 was $(498,594) compared to $14,501,569 for the same period in 2024 due to the factors described above.

Liquidity and Capital Resources

Going Concern

The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. The Company has an accumulated deficit of 295,774,377 and has a working capital deficit of $10,422,177 as of September 30, 2025, which raises substantial doubt about its ability to continue as a going concern.

The Company’s ability to continue as a going concern is dependent upon its ability to generate profitable operations in the future and/or obtain the necessary financing to meet its obligations and repay its liabilities arising from normal business operations when they come due. Management has plans to seek additional capital through some private placement offerings of debt and equity securities. These plans, if successful, will mitigate the factors which raise substantial doubt about the Company’s ability to continue as a going concern. These consolidated financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might result from this uncertainty.

Our cash and cash equivalent were $813 and $1,505 at September 30, 2025 and 2024, respectively. Cash provided by (used in) operating activities during the period ended September 30, 2025 was $688 compared to $28,522 during the same period in 2024. The amount provided by operating activities for the period ended September 30, 2025 was primarily related to a net loss of $498,594 and offset by changes in fair value of marketable securities of $2,185, accounts payable of $497,065 and accounts payable – related parties of $32. Our working capital position changed by going from a working capital deficit of $9,940,379 at December 31, 2024 to a working capital deficit of $10,422,177 at September 30, 2025.

We sustained net loss of $498,594 for the nine months ended September 30, 2025. In addition, we had an accumulated deficit of $295,774,377 and working capital deficit of $10,422,177 at September 30, 2025.

Dividends

The Company has not yet adopted any policy regarding payment of dividends. No cash dividends have been paid or declared since the Date of Inception.

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

As a Smaller Reporting Company, the Company is not required to include the disclosure under this Item.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including Mansour Khatib, who serves as our Chief Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended. Based upon that evaluation, our Chief Executive Officer and Principal Financial Officer has concluded that our disclosure controls and procedures were not effective as of the end of the applicable period to ensure that the information required to be disclosed by the Company in reports that it files or submits under the Exchange Act (i) is recorded, processed, summarized and reported within the time periods specified in Securities and Exchange Commission rules and forms, and (ii) is accumulated and communicated to our management, including our Chief Executive Officer, as appropriate to allow timely decisions regarding required disclosures.

As a smaller reporting company, with revenues stemming from recent acquisitions and a lack of profitability, the Company does not have the resources to install dedicated staff with deep expertise in all facets of SEC disclosure and GAAP compliance, and does not employ enough accounting staff to have proper separation of duties. As is the case with many smaller reporting companies, the Company will continue to consult with its external auditors and attorneys as it relates to new accounting principles and changes to SEC disclosure requirements. In order to correct this material weakness, the Company engaged a consultant with expertise in SEC disclosure and GAAP compliance. The Company found that this approach worked well in the past and believes it to be the most cost-effective solution available for the foreseeable future. The Company will conduct a review of existing sign-off and review procedures as well as document control protocols for critical accounting spreadsheets. The Company will also increase management’s review of key financial documents and records.

As a smaller reporting company, the Company does not have the resources to fund sufficient staff to ensure a complete segregation of responsibilities within the accounting function. However, Company management does review, and will increase the review of, financial statements monthly, and the Company’s external auditor conducts reviews on a quarterly basis. These actions, in addition to the improvements identified above, will minimize any risk of a potential material misstatement occurring.

Changes in Internal Control over Financial Reporting

There were no changes in the Company’s internal controls over financial reporting during the nine months ended September 30, 2025, that materially affected, or are reasonably likely to materially affect, the Company’s internal control over financial reporting.

MANAGEMENT’S INTERIM REPORT ON INTERNAL CONTROL OVER FINANCIAL REPORTING

Our management, consisting of our Chief Executive Officer (Principal Executive and Financial Officer), is responsible for establishing and maintaining adequate internal control over financial reporting. Internal control over financial reporting, as defined in Exchange Act Rule 13a-15(f) and 15d-15(f), is a process designed by, or under the supervision of, our principal executive and principal financial officers and effected by our Board of Directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and includes those policies and procedures that:

●

Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of our assets;

●

Provide reasonable assurance that transactions are recorded as necessary to permit preparation of our financial statements in accordance with generally accepted accounting principles, and that our receipts and expenditures are being made only in accordance with authorizations of our management and directors; and

●

Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use of disposition of our assets that could have a material effect on financial statements.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation.

Our management assessed the effectiveness of our internal control over financial reporting as of September 30, 2025. Based on this assessment, management believes that as of September 30, 2025, our internal control over financial reporting is not effective based on those criteria.

CHANGES IN INTERNAL CONTROL OVER FINANCIAL REPORTING

There were no changes during our last fiscal year that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II - OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

Legal Proceedings

Item 1A. Risk Factors.

As a Smaller Reporting Company, the Company is not required to include the disclosure under this Item 1A. Risk Factors. Despite the fact that we are not required to provide risk factors, we consider the following factors to be risks to our continued growth and development:

WE HAVE A LIMITED OPERATING HISTORY IN AN EVOLVING INDUSTRY, WHICH MAKES IT DIFFICULT TO EVALUATE OUR FUTURE PROSPECTS AND MAY INCREASE THE RISK THAT WE WILL NOT BE SUCCESSFUL.

We have a limited operating history in an evolving industry that may not develop as expected. Assessing our business and future prospects is challenging in light of the risks and difficulties we may encounter. These risks and difficulties include our ability to:

●

accurately forecast our revenues and plan our operating expenses;

●

successfully expand our business;

●

assimilate our acquisitions;

●

adapt to rapidly evolving trends in the ways consumers and businesses interact with technology;

●

avoid interruptions or disruptions in the offering of our products and our services;

●

develop a scalable, high-performance technology infrastructure that can efficiently and reliably handle increased usage, as well as the deployment of new features and products;

●

hire, integrate and retain talented sales, customer service, technology and other personnel; and

●

effectively manage rapid growth in personnel and operations; and

●

global COVID-19 pandemic

If the demand for our services and/or platforms/products offered or our products under development are not finalized, our business will be harmed. We may not be able to successfully address these risks and difficulties, which could harm our business and results of operations.

OUR LIMITED OPERATING HISTORY MAKES IT DIFFICULT FOR US TO EVALUATE OUR FUTURE BUSINESS PROSPECTS AND MAKE DECISIONS BASED ON THOSE ESTIMATES OF OUR FUTURE PERFORMANCE.

We have a limited operating history and, as a consequence, it is difficult, if not impossible, to forecast our future results based upon our historical data. Reliance on the historical results may not be representative of the results we will achieve. Because of the uncertainties related to our limited historical operations, we may be hindered in our ability to anticipate and timely adapt to increases or decreases in revenues or expenses. If we make poor budgetary decisions as a result of unreliable historical data, we could be less profitable or continue to incur losses.

OUR RESULTS OF OPERATIONS HAVE NOT RESULTED IN PROFITABILITY AND WE MAY NOT BE ABLE TO ACHIEVE PROFITABILITY GOING FORWARD

The Company does not accrue or capitalize development costs (or any costs to this effect) and expense it to its profit and loss statements as required by US GAAP. As such, the Company incurred a net loss of $489,142 for the nine months ended September 30, 2025. If we incur additional significant operating losses, our stock price, may decline, perhaps significantly. Our management is developing plans to alleviate the negative trends and conditions described above. Our business plan is speculative and unproven. There is no assurance that we will be successful in executing our business plan or that even if we successfully implement our business plan, that we will be able to curtail our losses now or in the future. Further, as we are an emerging enterprise, we expect that net losses will continue, and our working capital deficiency will increase.

WE HAVE NOT GENERATED POSITIVE CASH FLOW FROM OPERATIONS, AND OUR ABILITY TO GENERATE POSITIVE CASH FLOW IS UNCERTAIN. IF WE ARE UNABLE TO GENERATE POSITIVE CASH FLOW OR OBTAIN SUFFICIENT CAPITAL WHEN NEEDED, OUR BUSINESS AND FUTURE PROSPECTS WILL BE ADVERSELY AFFECTED AND WE COULD BE FORCED TO SUSPEND OR DISCONTINUE OPERATIONS.

Our operations have not generated positive cash flow for any period, and we have funded our operations primarily through the issuance of common stock and short-term and long-term debt and convertible debt. Our limited operating history makes an evaluation of our future prospects difficult. The actual amount of funds that we will need to meet our operating needs will be determined by a number of factors, many of which are beyond our control. These factors include the timing and volume of sales transactions, the success of our marketing strategy, market acceptance of our products, the success of our manufacturing and research and development efforts (including any unanticipated delays), our manufacturing and labor costs, the costs associated with obtaining and enforcing our intellectual property rights, regulatory changes, competition, technological developments in the market, evolving industry standards and the amount of working capital investments we are required to make.

Our ability to continue to operate until we are able to generate sufficient cash flow from operations will depend on our ability to generate sufficient positive cash flow from our operations. If we are unable to generate sufficient cash flow from our operations, our business and future prospects will be adversely affected and we could be forced to suspend or discontinue operations.

The Company had a stockholders’ deficit of $9,587,602 and an accumulated deficit of $295,774,377 at September 30, 2025.

WE WILL REQUIRE ADDITIONAL CAPITAL TO SUPPORT BUSINESS GROWTH, AND THIS CAPITAL MIGHT NOT BE AVAILABLE ON ACCEPTABLE TERMS, IF AT ALL.

We intend to continue to make investments to support our business growth and we will require additional funds to respond to business challenges, including the need to develop new features and products or enhance our existing products, improve our operating infrastructure or acquire complementary businesses and technologies. Further, we need additional capital to continue operations. Accordingly, we need to engage in equity or debt financing to secure additional funds. We expect that we have sufficient capital to maintain operations through the year 2025. In order to fully implement our business plan, we will need to raise about $10,000,000 If we raise additional funds through future issuances of equity or convertible debt securities, our existing stockholders could suffer significant dilution,

and any new equity securities we issue could have rights, preferences and privileges superior to those of holders of our common stock. Any debt financing that we secure in the future could involve restrictive covenants relating to our capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. We may not be able to obtain additional financing on terms favorable to us, if at all. If we are unable to obtain adequate financing or financing on terms satisfactory to us when we require it, our ability to continue to support our business growth and to respond to business challenges could be impaired, and our business may be harmed.

WE DEPEND UPON KEY PERSONNEL AND NEED ADDITIONAL PERSONNEL

Our success depends on our inability to attract and retain key personnel, including our existing personal, and our inability to do so may materially and adversely affect our business operations. The loss of qualified personnel could have a material and adverse effect on our business operations. Additionally, the success of the Company’s operations will largely depend upon its ability to successfully attract and maintain competent and qualified key management personnel. As with any company with limited resources, there can be no guaranty that the Company will be able to attract such individuals or that the presence of such individuals will necessarily translate into profitability for the Company.

OUR BUSINESS REQUIRES SUBSTANTIAL CAPITAL, AND IF WE ARE UNABLE TO MAINTAIN ADEQUATE CASH FLOWS FROM OPERATIONS OUR PROFITABILITY AND FINANCIAL CONDITION WILL SUFFER AND JEOPARDIZE OUR ABILITY TO CONTINUE OPERATIONS

We require substantial capital to support our operations. If we are unable to generate adequate cash flows from our operations, maintain adequate financing or other sources of capital are not available, we could be forced to suspend, curtail or reduce our operations, which could harm our revenues, profitability, financial condition and business prospects.

THERE IS CURRENTLY A LIMITED PUBLIC MARKET FOR OUR COMMON STOCK. FAILURE TO FURTHER DEVELOP OR MAINTAIN A TRADING MARKET COULD NEGATIVELY AFFECT THE VALUE OF OUR COMMON STOCK AND MAKE IT DIFFICULT OR IMPOSSIBLE FOR YOU TO SELL YOUR STOCK.

There is a limited public market for our Common Stock, which is traded on the OTC under the symbol GTCH. We cannot give any assurances that there will ever be a mature, developed market for our common stock. Failure to further develop or maintain an active trading market could negatively affect the value of our shares and make it difficult for you to sell your shares or recover any part of your investment in us. Even if a market for our common stock does develop in a material way, the market price of our common stock may be highly volatile. In addition to the uncertainties relating to our future operating performance and the profitability of our operations, factors such as variations in our interim financial results, or various, as yet unpredictable factors, many of which are beyond our control, may have a negative effect on the market price of our common stock.

IF WE FAIL TO MAINTAIN AN EFFECTIVE SYSTEM OF INTERNAL CONTROLS, WE MAY NOT BE ABLE TO ACCURATELY REPORT OUR FINANCIAL RESULTS OR PREVENT FRAUD. AS A RESULT, CURRENT AND POTENTIAL STOCKHOLDERS COULD LOSE CONFIDENCE IN OUR FINANCIAL REPORTING, WHICH WOULD HARM OUR BUSINESS AND THE TRADING PRICE OF OUR STOCK.

Effective internal controls are necessary for us to provide reliable financial reports and effectively prevent fraud. If we cannot provide reliable financial reports or prevent fraud, our brand and operating results could be harmed. We have in the past discovered, and may in the future discover, areas of our internal controls that need improvement. For example, for the years ended December 31, 2024 and 2023, we reported that our disclosure controls and procedures were not effective due to the lack of resources and the reliance on outside consultants. We intend to increase management’s review of our financials. We cannot be certain that these measures will ensure that we implement and maintain adequate controls over our financial processes and reporting in the future. Any failure to implement required new or improved controls, or difficulties encountered in their implementation, could harm our operating results or cause us to fail to meet our reporting obligations. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock.

Additional Risks Related to Our Common Stock

Because we are quoted on the OTC marketplace instead of a national securities exchange, our investors may experience significant volatility in the market price of our stock and have difficulty selling their shares.

Our Common Stock is currently quoted on the OTC Market Group’s OTC marketplace under the ticker symbol “GTCH”. The OTC is a regulated quotation service that displays real-time quotes and last sale prices in over-the-counter securities. Trading in shares quoted on the OTC is often thin and characterized by volatility. This volatility may be caused by a variety of factors, including the lack of readily available price quotations, the absence of consistent administrative supervision of bid and ask quotations, lower trading volume and market conditions. As a result, there may be wide fluctuations in the market price of the shares of our Common Stock for reasons unrelated to operating performance, and this volatility, when it occurs, may have a negative effect on the market price for our securities. Moreover, the OTC is not a stock exchange, and trading of securities on this platform is more sporadic than the trading of securities listed on a national quotation system or stock exchange. Accordingly, our stockholders may not be able to realize a fair price of their shares when they determine to sell them or may have to hold them for a substantial period of time until the market for our Common Stock improves.

Our stock price and trading volume may be volatile, which could result in substantial losses for our stockholders.

The equity trading markets may experience periods of volatility, which could result in highly variable and unpredictable pricing of equity securities. The market price of our Common Stock could change in ways that may or may not be related to our business, our industry or our operating performance and financial condition. In addition, the trading volume in our Common Stock has been low and may fluctuate and cause significant price variations to occur. We have experienced significant volatility in the price of our stock. In addition, the stock markets in general can experience considerable price and volume fluctuations.

We have not paid dividends in the past and have no immediate plans to pay cash dividends.

We plan to reinvest all of our earnings, to the extent we have earnings, to develop and deliver our products and cover operating costs and to otherwise become and remain competitive. We do not plan to pay any cash dividends with respect to our securities in the foreseeable future. We cannot assure you that we would, at any time, generate sufficient surplus cash that would be available for distribution to the holders of our Common Stock as a dividend. Therefore, you should not expect to receive cash dividends on our Common Stock.

Shares eligible for future sale may adversely affect the market for our Common Stock.

Of the 18,492,870,775 shares of our Common Stock outstanding as of the date of this Report, approximately 766,217,939 are restricted and 17,726,652,836 shares are freely tradable without restriction pursuant to Rule 144. Any substantial sale of our Common Stock pursuant to Rule 144 or pursuant to any resale prospectus may have a material adverse effect on the market price of our Common Stock.

You may experience future dilution as a result of future equity offerings.

To raise additional capital, we may in the future offer additional shares of our Common Stock or other securities convertible into or exchangeable for our Common Stock at prices that may not be the same as the price per share in this offering. We may sell shares or other securities in any future offering at a price per share that is lower than the price per share paid by investors in this offering, which would result in those newly issued shares being diluted. In addition, investors purchasing shares or other securities in the future could have rights superior to existing stockholders, which could impair the value of your shares. The price per share at which we sell additional shares of our Common Stock, or securities convertible or exchangeable into shares of our Common Stock, in future transactions may be higher or lower than the price per share paid by investors in this offering.

Our charter documents and Nevada law may inhibit a takeover that stockholders consider favorable.

Provisions of our certificate of incorporation and bylaws and applicable provisions of Nevada law may delay or discourage transactions involving an actual or potential change in control or change in our management, including transactions in which stockholders might otherwise receive a premium for their shares, or transactions that our stockholders might otherwise deem to be in their best interests. The provisions in our certificate of incorporation and bylaws:

●

limit who may call stockholder meetings;

●

do not provide for cumulative voting rights; and

●

provide that all vacancies may be filled by the affirmative vote of a majority of directors then in office, even if less than a quorum.

There are limitations on director/officer liability.

As permitted by Nevada law, our certificate of incorporation limits the liability of our directors for monetary damages for breach of a director’s fiduciary duty except for liability in certain instances. As a result of our charter provision and Nevada law, shareholders may have limited rights to recover against directors for breach of fiduciary duty. In addition, our certificate of incorporation provides that we shall indemnify our directors and officers to the fullest extent permitted by law.

Penny stock regulations may impose certain restrictions on the marketability of our securities.

The SEC adopted regulations which generally define a “penny stock” to be any equity security that has a market price of less than $5 per share or an exercise price of less than $5 per share, subject to certain exceptions. A security listed on a national securities exchange is exempt from the definition of a penny stock. Our Common Stock is not currently listed on a national security exchange. Our Common Stock is therefore subject to rules that impose additional sales practice requirements on broker-dealers who sell such securities to persons other than established customers and accredited investors (generally those with assets in excess of $1,000,000 or annual income exceeding $200,000, or $300,000 together with their spouse). For transactions covered by such rules, the broker-dealer must make a special suitability determination for the purchase of such securities and have received the purchaser’s written consent to the transaction prior to the purchase.

Additionally, for any transaction involving a penny stock, unless exempt, the rules require the delivery, prior to the transaction, of a risk disclosure document mandated by the SEC relating to the penny stock market. The broker-dealer must also disclose the commission payable to both the broker-dealer and the registered representative, current quotations for the securities and, if the broker-dealer is the sole market maker, the broker dealer must disclose this fact and the broker-dealer’s presumed control over the market. Finally, monthly statements must be sent disclosing recent price information for the penny stock held in the account and information on the limited market in penny stocks. Broker dealers must wait two business days after providing buyers with disclosure materials regarding a security before effecting a transaction in such security. Consequently, the “penny stock” rules restrict the ability of broker-dealers to sell our securities and affect the ability of investors to sell our securities in the secondary market and the price at which such purchasers can sell any such securities, thereby affecting the liquidity of the market for our Common Stock.

Stockholders should also be aware that, according to the SEC, the market for penny stocks has suffered in recent years from patterns of fraud and abuse. Such patterns include:

●

control of the market for the security by one or more broker-dealers that are often related to the promoter or issuer;

●

manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases;

●

“boiler room” practices involving high pressure sales tactics and unrealistic price projections by inexperienced sales persons;

●

excessive and undisclosed bid-ask differentials and markups by selling broker-dealers; and

●

the wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, along with the inevitable collapse of those prices with consequent investor losses.

FINRA sales practice requirements may limit a stockholder’s ability to buy and sell our stock.

The Financial Industry Regulatory Authority (referred to as FINRA) has rules requiring that, in recommending an investment to a customer, a broker-dealer must have reasonable grounds for believing that the investment is suitable for that customer. Prior to recommending speculative or low-priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives and other information. Under interpretations of these rules, FINRA has indicated its belief that there is a high probability that speculative or low-priced securities will not be suitable for at least some customers. If these FINRA requirements are applicable to us or our securities, they may make it more difficult for broker-dealers to recommend that at least some of their customers buy our Common Stock, which may limit the ability of our stockholders to buy and sell our common stock and could have an adverse effect on the market for and price of our common stock.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds.

During the nine months ended September 30, 2025, the Company issued 1,679,641,595 shares issued for the conversion of convertible notes of $16,796.

Item 3. Defaults Upon Senior Securities

Not Applicable

Item 4. Mine Safety Disclosures

Not Applicable.

Item 5. Other Information

During the quarter ended September 30, 2025, no director or officer adopted or terminated any Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement, as each term is defined in Item 408(a) of Regulation S-K.

ITEM 6. EXHIBITS, FINANCIAL STATEMENT SCHEDULES

No.		Description
3.1		Certificate of Incorporation of Forex International Trading Corp. (1)
3.2		Bylaws of Forex International Trading Corp. (1)
3.3		Certificate of Designation for Series A Preferred Stock (2)
3.4		Certificate of Designation for Series B Preferred Stock (3)
3.5		Certificate of Designation – Series C Preferred Stock (4)
3.6		Amendment to the Certificate of Designation for the Series B Preferred Stock (5)
3.7		Amendment to the Certificate of Designation for the Series C Preferred Stock(5)
3.8		Certificate of Change filed pursuant to NRS 78.209 (6)
3.9		Articles of Merger filed pursuant to NRS 92.A.200 (6)
3.10		Certificate of Amendment to the Articles of Incorporation of Gopher Protocol Inc. (8)
3.11		Certificate of Change dated July 10, 2019 (23)
3.12		Articles of Merger by and between Gopher Protocol Inc. and GBT Technologies Inc. dated July 10, 2019(23)
3.13		Certificate of Correction to the Certificate of Change (24)
3.14		Certificate of Correction to the Articles of Merger by and between Gopher Protocol Inc. and GBT Technologies Inc. dated July 10, 2019 (24)
3.15		Certificate of Amendment to the Articles of Incorporation of GBT Technologies Inc. dated September 23, 2019(26)
3.16		Certificate of Designation for Series B Preferred Stock (7)
3.17		Certificate of Designation of the Preferences, Rights and Limitations of the Series G Convertible Preferred Stock (15)
3.18		Series H Convertible Preferred Stock Certificate of Designation (21)
4.1		Form of Warrant issued to Robert Warren Jackson, Gregory Bauer, Michael Murray and Guardian Patch, LLC dated September 1, 2017 (14)
4.2		Balloon Note payable by Gopher Protocol Inc. to RWJ Advanced Marketing, LLC dated September 1, 2017 (14)
4.3		Form of Warrant issued to Derron Winfrey, Dennis Winfrey, Mark Garner and JIL Venture dated March 1, 2018 (16)
4.4		Note payable by Gopher Protocol Inc. to ECS, LLC dated March 1, 2018 (16)
4.5		Stock Option issued to Kevin Pickard dated April 16, 2018 (17)
4.6		Stock Option issued to Muhammad Khilji dated April 25, 2018 (18)
4.7		6% Convertible Note payable to Pablo Gonzalez dated June 17, 2019 (21)
4.8		Convertible Note payable to Glen Eagles Acquisition LP (22)
4.9		Amendment to Common Stock Purchase Warrant between Gopher Protocol Inc. and Glen Eagles Acquisition LP (22)
4.10		Second Amendment to Promissory Note between GBT Technologies Inc. and Ilaid Research and Trading LP dated July 20, 2020 (29)
4.11		Convertible Promissory Note August 4, 2020 issued to Redstart Holdings Corp. (30)
4.12		Fourth Amendment to Promissory Note between GBT Technologies Inc. and Iliad Research and Trading, L.P. dated May 14, 2020 – Executed May 19, 2021(31)
4.13		Convertible Promissory Note May 26, 2021 issued to Redstart Holdings Corp. – Executed on May 27, 2021 (32)
4.14		Fifth Amendment to Promissory Note between GBT Technologies Inc. and Iliad Research and Trading LP dated August 19, 2021 executed August 20, 2021 (33)
4.15		Convertible Promissory Note September 21, 2021 issued to Redstart Holdings Corp. – Executed on September 24, 2021, and Funded on September 28, 2021 (34)
4.16		Amended Loan Authorization and Agreement between GBT Technologies Inc. and U.S. Small Business Administration dated October 1, 2021 (35)
4.17		Convertible Promissory Note dated November 8, 2021 issued to Sixth Street Lending LLC (36)
4.18		Description of Securities (40)
4.19		Convertible Promissory Note dated May 4, 2022 issued to 1800 Diagonal Lending LLC (42)
10.1		Territorial License Agreement dated March 4, 2015, by and between Gopher Protocol Inc. and Hermes Roll LLC (7)
10.2		Amended and Restated Territorial License Agreement dated June 16, 2015 by and between Gopher Protocol Inc. and Hermes Roll LLC (9)
10.3		Letter Agreement dated August 20, 2015 by and between Gopher Protocol Inc. and Dr. Danny Rittman (10)

10.4		Letter Agreement dated March 14, 2016 by and between Gopher Protocol Inc. and Dr. Danny Rittman. (11)
10.5		Amended and Restated Employment Agreement by and between Gopher Protocol Inc. and Dr. Danny Rittman dated April 19, 2016 (12)
10.6		Letter Agreement between the Company and Danny Rittman dated June 29, 2017 (13)
10.7		Asset Purchase Agreement between Gopher Protocol Inc. and RWJ Advanced Marketing, LLC dated September 1, 2017 (14)
10.8		Addendum to Asset Purchase Agreement between Gopher Protocol Inc. and RWJ Advanced Marketing, LLC dated September 1, 2017 (14)
10.9		Employment Agreement between Gopher Protocol Inc. and Gregory Bauer dated September 1, 2017 (14)
10.10		Asset Purchase Agreement between Gopher Protocol Inc. and ECS Prepaid LLC dated March 1, 2018 (16)
10.11		Employment Agreement between Gopher Protocol Inc. and Derron Winfrey dated March 1, 2018(16)
10.12		Employment Agreement between Gopher Protocol Inc. and Mark Garner dated March 1, 2018(16)
10.13		Agreement between Gopher Protocol Inc. and Mobiquity Technologies, Inc. dated September 4, 2018 (19)
10.14		Exclusive Intellectual Property License and Royalty Agreement between Gopher Protocol Inc. and GBT Technologies, S.A. dated September 14, 2018 (20)
10.15		Letter Agreement between Gopher Protocol Inc. and Dr. Danny Rittman dated September 14, 2018 (20)
10.16		Exchange Agreement entered into between Gopher Protocol Inc., Altcorp Trading LLC, GBT Technologies, S.A., a Costa Rica company and Pablo Gonzalez dated June 17, 2019 (21)
10.17		Consulting Agreement entered into between Gopher Protocol Inc. and Glen Eagles Acquisition LP (22)
10.18		Letter Agreement between Mobiquity Technologies, Inc. and GBT Technologies Inc. executed August 2, 2019 Delivered August 6, 2019 (39)
10.19		Stock Purchase Agreement between Mobiquity Technologies, Inc. and GBT Technologies Inc. Dated September 10, 2019 (25)
10.20		Stock Purchase Agreement between Marital Trust GST Subject U/W/O Leopold Salkind and GBT Technologies Inc. dated September 10, 2019 (25)
10.21		Letter Agreement between GBT Technologies Inc. and Stanley Hills LLC dated February 26, 2020 (27)
10.22		Amendment to Promissory Note between GBT Technologies Inc. and Iliad Research and Trading, L.P. dated February 27, 2020 (27)
10.23		Order dated February 27, 2020 issued by the United States District Court District of Nevada (27)
10.24		Joint Venture and Territorial License Agreement by and between GBT Technologies Inc. and Tokenize-It S.A. dated March 6, 2020 (28)
10.25		Consulting Agreement by and between Pablo Gonzalez and GBT Tokenize Corp. dated March 6, 2020 (28)
10.26		Pledge Agreement by and between GBT Tokenize Corp. and Tokenize-It S.A., dated March 6, 2020 (28)
10.27		Securities Purchase Agreement dated August 4, 2020 between GBT Technologies Inc. and Redstart Holdings Corp. (30)
10.28		Securities Purchase Agreement dated November 8, 2021 between GBT Technologies Inc. and Sixth Street Lending LLC (36)
10.29		Equity Financing Agreement between GBT Technologies Inc. and GHS Investments LLC dated December 17, 2021 (37)
10.30		Registration Rights Agreement between GBT Technologies Inc. and GHS Investments LLC dated December 17, 2021 (37)
10.31		Resolution of Purchase, Mutual Release and Settlement Agreement by and among GBT Technologies Inc. and Parties Listed Therein December 22, 2021(38)
10.33		Form of Claim Purchase Agreement dated April 12, 2022 (41)
10.34		Finders Fee Agreement between JH Darbie & Co. and GBT Technologies Inc. dated October 14, 2021 (39)
10.35		Master Joint Venture and Territorial License Agreement by and between GBT Technologies Inc. and Magic International Argentina FC SL (41)
10.36		Pledge Agreement by and between GBT Tokenize Corp and Magic International Argentina FC SL (41)
10.37		Securities Purchase Agreement dated May 4, 2022 between GBT Technologies Inc. and 1800 Diagnol Lending LLC (42)
31.1		Certification of Chief Executive Officer (Principal Executive and Financial Officer) pursuant to Rule 13a-14(a) or Rule 15d-14(a) as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1		Certification of Chief Executive Officer (Principal Executive and Financial Officer) pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

(1)		Incorporated by reference to the Form S-1 Registration Statement filed with the SEC on September 9, 2009.
(2)		Incorporated by reference to the Form 10-K Annual Report filed with the Securities and Exchange Commission on April 6, 2011
(3)		Incorporated by reference to the Form 10-Q Quarterly Report filed with the Securities and Exchange Commission on May 14, 2012
(4)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on September 27, 2012.
(5)		Incorporated by reference to the Form 10-Q Quarterly Report filed with the Securities and Exchange Commission on November 20, 2012.
(6)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on February 18, 2015
(7)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on March 12, 2015
(8)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on May 1, 2015
(9)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on June 16, 2015
(10)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on August 21, 2015
(11)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on April 20, 2016
(12)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on April 20, 2016
(13)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on September 30, 2017
(14)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on September 7, 2017
(15)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on January 3, 2018
(16)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on March 21, 2018
(17)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on April 18, 2018
(18)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on April 26, 2018.
(19)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on September 9, 2018.
(20)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on September 18, 2018.
(21)		Incorporated by reference to the Form 10-Q Quarterly Report filed with the Securities and Exchange Commission on June 19, 2019.
(22)		Incorporated by reference to the Form 10-Q Quarterly Report filed with the Securities and Exchange Commission on July 12, 2019.
(23)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on July 15, 2019.
(24)		Incorporated by reference to the Form -8-K Current Report filed with the Securities and Exchange Commission on August 5, 2019.
(39)		Incorporated by reference to the Form 10-Q Quarterly Report filed with the Securities and Exchange Commission on August 7, 2019.
(25)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on September 16, 2019.

(26)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on September 25, 2019.
(27)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on March 2, 2020.
(28)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on March 11, 2020.
(29)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on July 24, 2020.
(30)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on August 10, 2020.
(31)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on May 21, 2021.
(32)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on June 1, 2021.
(33)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on August 23, 2021.
(34)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on September 29, 2021.
(35)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on October 6, 2021.
(36)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on November 11, 2021
(37)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on December 20, 2021
(38)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on December 28, 2021
(39)		Incorporated by reference to the Form S-1 Registration Statement filed with the Securities and Exchange Commission on January 12, 2022
(40)		Incorporated by reference to the Form 10-K Annual Report filed with the Securities and Exchange Commission on March 25, 2022
(41)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on April 18, 2022
(42)		Incorporated by reference to the Form 8-K Current Report filed with the Securities and Exchange Commission on May 10, 2022

SIGNATURES

In accordance with Section 13 or 15(d) of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, there unto duly authorized.

	GBT TECHNOLOGIES INC.
	(Registrant)

Date: November 14, 2025	By:	/s/ Michael Murray
		Michael Murray
		Chief Executive Officer
Date: November 14, 2025	By:	/s/ Mansour Khatib
		Mansour Khatib
		Secretary & Director

GBT Technologies Inc. 10-Q